6-K

1

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission file number: 001-41842

Abivax SA

(Exact name of Registrant as specified in its charter and translation of Registrant’s name into English)

7-11 boulevard Haussmann

75009 Paris, France

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-

F.

Form 20-F ☒ Form 40-F ☐

2

On September 8, 2025, Abivax SA (the "Registrant") announced its financial results as of and for the three and six

months ended June 30, 2025 and issued a press release and its unaudited interim condensed consolidated financial

statements, copies of which are attached hereto as Exhibits 99.1 and 99.2, respectively, and incorporated herein by

reference.

Incorporation by Reference

This Report on Form 6-K, including Exhibits 99.1 and 99.2, except for the quotes contained therein, shall be deemed

to be incorporated by reference into the Registrant’s registration statements on Form F-3 (File No. 333-283336),

Form F-3 (File No. 288884) and Form S-8 (File No. 333-286069) and to be part thereof from the date on which this

Report is filed, to the extent not superseded by documents or reports subsequently filed.

Exhibit Index
Exhibit 99.1	Press release, dated September 8, 2025
Exhibit 99.2	Unaudited Interim Condensed Consolidated Financial Statements

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be

signed on its behalf by the undersigned, thereunto duly.

	Abivax SA<br><br>(Registrant)
Date: September 8, 2025	/s/ Marc de Garidel
	Chief Executive Officer

4

Exhibit 99.2

Unaudited Interim Condensed Consolidated Financial Statements

TABLE OF CONTENTS

	Page
INTRODUCTION.................................................................................................................	1
RISK FACTORS...................................................................................................................	3
OPERATING RESULTS........................................................................................................	4		INDEX TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL<br><br>STATEMENTS.........................................................	F-1
---	---

5

INTRODUCTION

Unless otherwise indicated or the context otherwise requires, “Abivax,” “the Company,” “the Group,” “we,” “us”

and “our” refer to Abivax SA and its consolidated subsidiary, taken as a whole.

“Abivax” and the Abivax logo and other trademarks or service marks of Abivax SA appearing in this half-year

report are the property of Abivax SA. Solely for convenience, the trademarks, service marks and trade names

referred to in this half-year report are listed without the ® and ™ symbols, but such references should not be construed

as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their right

thereto. All other trademarks, trade names and service marks appearing in this half-year report are the property of

their respective owners. We do not intend to use or display other companies’ trademarks and trade names to imply

any relationship with, or endorsement or sponsorship of us by, any other companies.

This half-year report includes our unaudited interim condensed consolidated financial statements of financial

position as of June 30, 2025 and December 31, 2024 and the related unaudited condensed consolidated statements of

loss and comprehensive loss for each of the three- and six-month periods ended June 30, 2025 and June 30, 2024

and the unaudited condensed consolidated statements of cash flows and changes in shareholder's equity for the six-

month periods ended June 30, 2025 and June 30, 2024, prepared in accordance with International Financial

Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and adopted by

the European Union ("EU") regulation n°1606/2022 of July 19, 2022. None of our financial statements were

prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). Our financial statements

are presented in euros and, unless otherwise stated, all monetary amounts are in euros. All references in this half-

year report to “$”, “U.S. dollars” and “dollars” mean U.S. dollars, and all references to “€”, “EUR” and “euros”

mean European Monetary Union euros, unless otherwise noted. Throughout this half-year report, references to

"ADSs" mean American Depositary Shares (“ADSs”) or ordinary shares represented by such ADSs, as the case may

be.

Special Note Regarding Forward-Looking Statements

This half-year report contains forward-looking statements within the meaning of Section 27A of the Securities Act

of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended ("Exchange Act"), that

are based on our management’s beliefs and assumptions and on information currently available to our management.

All statements other than present and historical facts and conditions contained in this half-year report, including

statements regarding our future results of operations and financial positions, business strategy, plans and our

objectives for future operations, are forward-looking statements. When used in this half-year report, the words

“anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “plan,”

“will,” “would,” “potential,” “predict,” “objective,” “should,” or the negative of these and similar expressions

identify forward-looking statements. Forward-looking statements include, but are not limited to, statements about:

•the prospects of attaining, maintaining and expanding marketing authorization for our drug candidates;

•the potential attributes and clinical advantages of our drug candidates;

•the initiation, timing, progress and results of our preclinical and clinical trials (and those conducted by third

parties) and other research and development programs;

•the timing of the availability of data from our clinical trials;

•the timing of and our ability to advance drug candidates through clinical development;

•the timing or likelihood of regulatory meetings and filings;

•the timing of and our ability to obtain and maintain regulatory approvals for any of our drug candidates;

•our ability to identify and develop new drug candidates from our preclinical studies;

•our ability to develop sales and marketing capabilities and transition into a commercial-stage company;

•the effects of increased competition as well as innovations by new and existing competitors in our industry;

•our ability to enter into strategic relationships or partnerships;

•our ability to obtain, maintain, protect and enforce our intellectual property rights and propriety

technologies and to operate our business without infringing the intellectual property rights and proprietary

technology of third parties;

•our expectations regarding our cash requirements;

6

•our estimates regarding expenses, future revenues, capital requirements and the need for additional

financing;

•the impact of government laws and regulations;

•our competitive position; and

•unfavorable conditions in our industry, the global economy or global supply chain, including financial and

credit market fluctuations, international trade relations, political turmoil, natural catastrophes, warfare (such

as the Russia-Ukraine war and the Israel-Hamas war), and terrorist attacks.

We encourage you to read and carefully consider all of the risk factors disclosed in our annual report on Form 20-F

for the year ended December 31, 2024 filed with the Securities and Exchange Commission (“SEC”) on March 24,

2025 (the “Annual Report”) under the caption “Item 3.D—Risk Factors” for a more complete understanding of the

risks and uncertainties material to our business, including important factors that may cause our actual results to

differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we

cannot assure you that the forward-looking statements in this document will prove to be accurate. Furthermore, if

our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant

uncertainties in these forward-looking statements, you should not regard these statements as a representation or

warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at

all. These forward-looking statements represent our plans, objectives, estimates, expectations and intentions only as

of the date of this filing. We undertake no obligation to publicly update any forward-looking statements, whether as

a result of new information, future events or otherwise, except as required by law.

You should read this document and the documents that we reference herein completely and with the understanding

that our actual future results may be materially different from what we expect. We qualify all of our forward-looking

statements by these cautionary statements.

This half-year report contains market data and industry forecasts that were obtained from industry publications.

These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such

estimates. We have not independently verified any third-party information. While we believe the market position,

market opportunity and market size information included in this half-year report is generally reliable, such

information is inherently imprecise.

Rounding of Figures

Certain figures (including data expressed in thousands or millions of euros or dollars) and the percentages presented

in this half-year report have been rounded up or down. Accordingly, totals given may vary slightly from those

obtained by adding the exact (unrounded) values of those same figures.

7

RISK FACTORS

The Company’s business faces significant risks. You should carefully consider all of the information set forth in this

document and in the Company’s other filings with the SEC, including the risk factors which the Company faces and

which are faced by the Company’s industry described in “Item 3.D—Risk Factors” of the Company’s Annual

Report on Form 20-F for the fiscal year ended December 31, 2024. Our risk factors have not changed materially

from those described in our Annual Report on Form 20-F. Our business, financial condition or results of operations

could be materially adversely affected by any of these risks.

8

OPERATING RESULTS

Overview

We are a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s

natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Our

lead drug candidate, obefazimod, is currently being evaluated in the following indications:

•Ulcerative colitis (“UC”): Phase 3 clinical trials for the treatment of adults with moderately to severely

active UC are ongoing (“ABTECT”).  On July 22, 2025, we announced the positive Phase 3 results of our

ABTECT 8-week induction trials. Top-line results from the 44-week maintenance data read-out expected

during the second quarter of 2026.

•Crohn’s disease (“CD”): On October 3, 2024, we announced the first patient enrolled in our ENHANCE-

CD Phase 2b clinical trial of obefazimod in patients with CD with the 12-week induction data read-out

expected in second half of 2026.

•Combination therapy: In September 2024, we announced initial preclinical combination data of obefazimod

combined with etrasimod in a mouse model of inflammatory bowel diseases (“IBD"). The results showed

that treatment with the combination improved the response on body weight protection and Disease Activity

Index and a synergistic and statistically significant reduction of several cytokines (TNFa, IL-17, IL-6,

IFNg) in the blood compared to each drug alone. Additional preclinical data to support our decision-making

on a combination agent is expected in 2025.

In addition, we have launched a research and development program to generate new potential drug candidates

to strengthen our intellectual property portfolio on the miR-124 platform and to identify additional drug candidates

from our proprietary small molecule library that includes additional miR-124 enhancers. We expect to announce a

follow-on candidate selection in a new indication in the second half of 2025.

Results of Operations

The following table sets forth our results of operations for the six months ended June 30, 2024 and 2025.

The following discussion covers these periods. It also covers all the material changes in financials conditions

and results of operations, if any, for the three months ended June 30, 2024 and June 30, 2025, for which unaudited

consolidated statements of loss are presented in the accompanying financial statements, in addition to the six months

ended June 30, 2024 and June 30, 2025.

(In thousands of euros)	Six-Month Ended<br><br>June 30, 2024	Six-Month Ended<br><br>June 30, 2025	% 2024 Change
Other operating income .........................................................	6,815	2,087	(69)%
Total operating income ..................................................................	6,815	2,087	(69)%
Sales and marketing expenses .................................................	(4,229)	(1,534)	(64)%
Research and development expenses ......................................	(64,650)	(77,946)	21%
General and administrative expenses ....................................	(17,932)	(16,303)	(9)%
Total operating expenses ...............................................................	(86,811)	(95,783)	10%
Operating loss .................................................................................	(79,997)	(93,696)	17%
Financial expenses .................................................................	(9,514)	(10,857)	14%
Financial income ....................................................................	7,873	3,769	(52)%
Financial income (loss) ..................................................................	(1,641)	(7,088)	332%
Net loss before tax ..........................................................................	(81,638)	(100,784)	23%
Income Tax .............................................................................	—	—	—%
Net loss for the period ....................................................................	(81,638)	(100,784)	23%

Total Operating Income

For the six months ended June 30, 2025, our total operating income was €2.1 million, as compared to

€6.8 million for the six months ended June 30, 2024, a decrease of (69)% as detailed below.

Other Operating Income

The following table sets forth our other operating income for the six months ended June 30, 2024 and 2025.

(In thousands of euros)	Six-Month<br><br>Ended June 30,<br><br>2024	Six-Month<br><br>Ended June 30,<br><br>2025	% 2024 Change
CIR (Research Tax Credits) ..............................................................	2,665	2,017	(24)%
Subsidies ...........................................................................................	4,121	—	(100)%
Other .................................................................................................	29	70	139%
Total other operating income ........................................................	6,815	2,087	(69)%

For the six months ended June 30, 2025, our other operating income was €2.1 million, as compared to

€6.8 million for the six months ended June 30, 2024.

10

Research Tax Credits

For the six months ended June 30, 2025, we recognized research tax credits for our research and development

projects of €2.0 million, as compared to €2.7 million for the six months ended June 30, 2024. Although research and

development expenses for the six months ended June 30, 2025 increased by 21% as compared to the six months

ended June 30, 2024, the €0.7 million decrease is mainly driven by (i) the maximum amount of eligible outsourced

research and development expenses being capped and internal research and development costs being stable, (ii) the

reimbursement of the CARENA and RNP-VIR conditional advances, deducted from the CIR calculation (for €0.4

million) and (iii) a change in the CIR regulation related to eligible expenses (for €0.2 million).

Subsidies

For the six months ended June 30, 2025, our subsidy income was nil, as compared to €4.1 million for the six

months ended June 30, 2024. The decrease is related to the RNP-VIR and CARENA conditional advances granted

by Bpifrance between 2013 and 2019. Following the termination of both projects, in June 2024, Bpifrance agreed to

waive 60% of the remaining conditional advances and accrued interests, resulting in a non-cash subsidy income of

€4.1 million (see Bpifrance - Conditional Advances and Subsidies within the "Liquidity and Capital Resources"

section).

Total Operating Expenses

For the six months ended June 30, 2025, our total operating expenses were €95.8 million, as compared to

€86.8 million for the six months ended June 30, 2024, an increase of €9.0 million, or 10%. This increase was

primarily due to an increase in research and development expenses of €13.3 million  partially offset by a decrease in

sales and marketing expenses of €2.7 million, and a decrease in general and administrative expenses of €1.63

million, each as described below.

Sales and Marketing Expenses

For the six months ended June 30, 2025, our total sales and marketing expenses were €1.5 million, as

compared to €4.2 million for the six months ended June 30, 2024, a decrease of €2.7 million. The decrease was

predominantly driven by a reduction in headcount as well as one-time costs that were incurred in 2024 for the

Group's corporate re-branding, including its new website.

Research and Development Expenses

The following table sets forth our research and development expenses by drug candidate and therapeutic

indication for the six months ended June 30, 2024 and 2025.

(In thousands of euros)	Six-Month<br><br>Ended June 30,<br><br>2024	Six-Month<br><br>Ended June 30,<br><br>2025	% 2024<br><br>Change
Obefazimod ............................................................................................	€62,015	€75,345	21%
Ulcerative Colitis ...........................................................................	51,752	51,929	—%
Crohn’s Disease .............................................................................	917	7,416	709%
Obefazimod Other Indication ........................................................	257	1,171	356%
Transversal activities .....................................................................	9,089	14,829	63%
Others .....................................................................................................	2,636	2,601	(1)%
Research and development expenses ...................................................	€64,650	€77,946	21%

11

For the six months ended June 30, 2025, our research and development expenses were €77.9 million, as

compared to €64.7 million for the six months ended June 30, 2024, an increase of €13.3 million, or 21%. This

increase was primarily due to a €6.5 million increase in expenses related to our CD program, resulting from the

progression of our Phase 2b trials in CD, and a €5.7 million increase in transversal activities related to the overall

expansion of the research and development headcount to support our organizational growth and the issuance of new

equity awards to officers and employees in research and development. Expenses related our UC clinical program

remained stable, increasing by €0.2 million, or 0.3%.

General and Administrative Expenses

(In thousands of euros)	Six-Month<br><br>Ended June<br><br>30, 2024	Six-Month<br><br>Ended June 30,<br><br>2025	% 2024<br><br>Change
Personnel costs .....................................................................................	11,172	9,932	(11)%
Consulting and professional fees ..........................................................	3,848	3,703	(4)%
Other general and administrative expenses ..........................................	2,912	2,668	(8)%
General and administrative expenses ...............................................	17,932	16,303	(9)%

For the six months ended June 30, 2025, our general and administrative expenses were €16.3 million, as

compared to €17.9 million for the six months ended June 30, 2024, a decrease of €1.6 million, or 9%. This decrease

was primarily due to a decrease in personnel costs of €1.2 million, or 11%, mainly resulting from the expense

recognition pattern of equity awards granted to certain of our officers and employees, many of which were issued in

connection with our U.S. initial public offering and listing on Nasdaq in October 2023, as well as strict adherence to

the approved budget, which includes savings through reducing non-essential spend. These were partially offset by

increased legal and professional fees and other costs associated with operating as a dual-listed public company.

Operating Loss

For the six months ended June 30, 2025, our net operating loss was €93.7 million, as compared to a net

operating loss of €80.0 million for the six months ended June 30, 2024, an increase of €13.7 million, or 17%. This

increase was primarily due to an increase of €13.3 million in research and development expenses, partially offset by

a decrease of €2.7 million in sales and marketing expenses.

Financial Income (Loss)

For the six months ended June 30, 2025, our net financial loss was €7.1 million, as compared to a net

financial loss of €1.6 million for the six months ended June 30, 2024.

For the six months ended June 30, 2025, our net financial loss was mainly driven by interest expenses of €6.9

million in relation to the first tranche of senior secured convertible bonds with warrants attached in the Kreos /

Claret Financing (the “Kreos / Claret OCABSA”), the second and third tranches of the senior secured bonds in the

Kreos / Claret Financing (drawn on March 28, 2024 and June 21, 2024 respectively) and the senior convertible notes

in the Heights Financing (the "Heights Convertible Notes"), non-cash expense of €1.1 million in relation to our

royalty certificates and foreign exchange losses of €2.3 million (including the €0.4 million non-cash impact of the

revaluation of U.S. dollar-denominated cash and cash equivalents as of June 30, 2025). These costs were partially

offset mainly by interest income of €1.1 million in relation to the invested proceeds from our U.S. initial public

offering and listing on Nasdaq, a non-cash income of €1.3 million related to the decrease in the fair value of the

Heights convertible notes and a €0.5 million income related to the fair value changes of certain of our cash

equivalents.

For the six months ended June 30, 2024, our net financial loss was mainly driven by interest expenses of €4.2

million in relation to the first tranche of the Kreos / Claret OCABSA, the second and third tranches of senior secured

bonds in the Kreos / Claret Financing (drawn on March 28, 2024 and June 21, 2024, respectively) and the Heights

Convertible Notes and €1.9 million in relation to our royalty certificates, a €1.5 million increase in the fair value of

12

derivatives and transaction costs amounting to €1.6 million. These costs were partially offset mainly by an interest

income of €4.8 million in relation to the invested proceeds from our U.S. initial public offering and listing on

Nasdaq and foreign exchange gains of €2.3 million (including the €1.8 million non-cash impact of the revaluation of

U.S. dollar-denominated cash and cash equivalents as of June 30, 2024).

Income Taxes

For each of the six months ended June 30, 2024 and 2025, our income tax charge was zero.

Net Loss

For the six months ended June 30, 2025, our net loss for the period was €100.8 million, as compared to

€81.6 million for the six months ended June 30, 2024, an increase of €19.1 million, or 23%.

Liquidity and Capital Resources

Sources of Liquidity

We have incurred substantial operating losses since inception and expect to continue to incur significant

operating losses for the foreseeable future and may never become profitable. For the six-month periods ended June

30, 2024 and 2025, we reported net losses of €81.6 million and €100.8 million, respectively. As of December 31,

2024, we carried forward accumulated tax losses of €609.4 million.

Since inception, we have financed our operations through the issuance of ordinary shares with gross aggregate

proceeds of €1,194.7 million,of which €130.0 million of gross proceeds were from offerings of our ordinary shares

on Euronext Paris in February 2023, €223.3 million of gross proceeds were from offering of our ordinary shares in

the form of ADS on the Nasdaq Global Market in our U.S. initial public offering as well as ordinary shares in

Europe (including France) and countries outside of the United States in a private placement in October 2023, €637.5

million of gross proceeds were from the offering of our ordinary shares in the form of ADS on the Nasdaq Global

Market in July 2025 ("the Offering"), bank borrowings and structured loans for €175.0 million, reimbursements of

CIR in an amount of €41.3 million, subsidies received from Bpifrance (including €21.3 million of subsidies and €1.8

million of conditional advances) and royalty certificates in an amount of €2.9 million.

In addition, on November 19, 2024, we entered into an equity distribution agreement with Piper Sandler & Co.

(“Piper Sandler”) allowing us to issue and sell from time to time, in one or more "at the market" offerings through

Piper Sandler acting as sales agent, ordinary shares in the form of ADSs, each ADS representing one ordinary share,

nominal value of €0.01 per share, with aggregate gross sales proceeds of up to $150.0 million (the "ATM Program").

To date, we have not sold any ADSs pursuant to the ATM Program.

Based on (a) our existing cash and cash equivalents of €60.9 million as of June 30, 2025, (b) the gross

proceeds from the July 2025 Offering of €637.5 million and (c) the conversion of all 350 Heights convertible notes

in July and August 2025, we expect, as of the date of issuance of the unaudited interim condensed consolidated

financial statements included in this half-year report, to be able to fund our forecasted cash flow requirements into

the fourth quarter of 2027, allowing us to reach 12 months of expected cash runway post the planned NDA

submission for UC, assuming positive results from its Phase 3 maintenance trial. Our forecasted cash flow

requirements take into account our assumption of continued R&D expenditure related to the continuation of the

Phase 3 clinical trials of obefazimod in UC, progression of the Phase 2b clinical trials for CD and the initial stages of

the scale up of the commercial organization as we prepare for a potential launch of obefazimod in UC.

Based on the above, management has concluded that the substantial doubt about our ability to continue as a

going concern has been alleviated beyond 12 months from the date of issuance of the financial statements

accompanying this half-year report, and the accompanying financial statements have been prepared on a going

concern basis.

13

Capital Increases

During the six-month period ending June 30, 2025, there has been one capital increase relating to the vesting

of 124,096 AGAs, resulting in the issuance of 124,096 ordinary shares with a par value of €0.01 per share.

On July 28, 2025, we received gross proceeds of €637.5 million from the issuance of 11,679,400 ordinary

shares in the form of ADSs, at a price of $64.00 per share (corresponding to €54.58 per ordinary share). We intend

to use the net proceeds from the Offering as follows:

•approximately $140.0 (€119.4) million to $185.0 (€157.8) million to fund the clinical development of

obefazimod for UC;

•approximately $30.0 (€25.6) million to $65.0 (€55.4) million to fund the clinical development of

obefazimod for CD; and

•the remainder for working capital and for other general corporate purposes, including preparation of

commercialization, additional research and development and financing expenses.

Research Tax Credits

From our inception to June 30, 2025, we have benefited from refunds of CIRs in a total amount of €41.3

million. In November 2024, we received CIRs of €4.5 million with respect to the year ended December 31, 2023. In

June 2025, we received CIRs of €5.7 million with respect to the year ended December 31, 2024.

Bpifrance—Conditional Advances and Subsidies

We have received several conditional advances and subsidies from Bpifrance since our inception. Funds

received from Bpifrance in the form of conditional advances are recognized as financial liabilities, as we have a

contractual obligation to reimburse Bpifrance for such conditional advances in cash based on a repayment schedule.

Each award of an advance is made to help fund a specific development milestone. Subsidies are non-repayable

grants, which are recognized in the financial statements when there exists reasonable assurance that we will comply

with the conditions attached to the subsidies and the subsidies will be received.

Bpifrance—CARENA Contract

As part of the development of therapeutic and diagnostic solutions targeting alternative splicing and RNA

interference in the fields of virology (HIV-AIDS, HTLV-1) and metabolism (obesity), SPLICOS, which we acquired

in October 2014, entered into a Master Support Agreement and a conditional advance contract in December 2013 for

the “CARENA” Strategic Industrial Innovation Project (“CARENA project”), with Bpifrance. Under this contract,

we were eligible to receive up to €3.8 million in conditional advances to develop a therapeutic HIV treatment

program with obefazimod. As of December 31, 2024 (year during which the program was terminated), we had

received €3.4 million of conditional advances and subsidies in total.

In June 2024, the Company and Bpifrance agreed to terminate the project due to technical failure.

Bpifrance granted an additional amount of €1.1 million payable to the Company to reimburse additional expenses

incurred as part of the project, and agreed to waive 60% of the remaining conditional advance of €3.3 million and

accrued interests, for which we recognized a subsidy income of €2.3 million in the aggregate. We repaid the

outstanding amounts during the second half of 2024.

Bpifrance—RNP-VIR Contract

As part of the CARENA project, focused on the clinical development of a drug molecule and demonstrating

the validity of an innovative therapeutic approach targeting viral RNPs, we entered into a Master Support

Agreement with Bpifrance, as well as a beneficiary agreement dated March 21, 2017, with conditional advances for

the “RNP-VIR” structuring research and development project for competitiveness. Under the RNP-VIR contract, we

were eligible to receive up to €6.3 million in conditional advances to develop methods for the discovery of new

molecules for the treatment of viral infectious diseases through the development of the “Modulation of RNA

biogenesis” platform. As of December 31, 2024 (year during which the program was terminated), we had received

€3.9 million of conditional advances and subsidies in total.

In June 2024, the Company and Bpifrance agreed to terminate the project due to technical failure.

Bpifrance claimed the reimbursement of €1.2 million corresponding to overpayments of conditional advances and

subsidies (for which the Group had not incurred the corresponding R&D expenses) and agreed to waive 60% of the

14

remaining advances of €3.0 million and accrued interests, for which the Group recognized a subsidy income of €1.9

million in the aggregate. We repaid the outstanding amounts during the second half of 2024.

Bpifrance—Ebola

The Bpifrance and Occitanie Region joint support agreement was entered into on June 2, 2017 and provides

for conditional advances for a total amount of €0.4 million (€0.1 million from the Languedoc Roussillon Midi

Pyrénées Region and €0.3 million from Bpifrance) for the Ebola program. All funds under this contract were

received. In September 2019, we terminated this program due to the imminent licensing of a competing vaccine for

this indication, as well as changes in the macroeconomic climate for public funding. The reimbursement of the

conditional advance was spread over the period from September 2019 to June 2024.

Indebtedness

For a description of material financing agreements, see "Item 10.C. Material Contracts" of the Company’s

2024 Annual Report on Form 20-F.

During the six-month period ended June 30, 2025, we did not enter into any new financing agreements.

On July 23 and July 30, 2025, we received notices from entities affiliated with Heights Capital Management,

which hold amortizing senior convertible notes issued in August 2023 (the “Height Convertible Notes”), for the

conversion of 150 and 200 convertible notes (corresponding to the entirety of the outstanding principal amount of

€21.9 million) into an aggregate of 920 377 new ordinary shares of the Group at a conversion price of €23.7674 per

ordinary share in accordance with the terms and conditions of the convertible notes. Following these share issuances,

we no longer hold any debt with Heights Capital Management.

On August 6, 2025, Kreos Capital VII(UK) Limited converted its Tranche A portion (OCABSA) of the

Kreos / Claret Financing Agreement, resulting in the issuance of 785,389 ordinary shares if the Group. In addition,

on the same date, Kreos Capital VII Aggregator SCSp exercised all of its share warrants (the tranche A-B BSA and

tranche C BSA) resulting in the issuance of 319,251 ordinary shares of the Group.

On August 28, 2025, Claret European Growth Capital Fund III SCSp, exercised its share warrants (the

tranche A-B BSA and tranche C BSA) resulting in the issuance of respectively 319,251 shares 206,662 shares of the

Group.

Historical Changes in Cash Flows

The following table sets forth our cash inflows and outflows for the six-month periods ended June 30, 2024

and 2025.

(In thousands of euros)	Six-Month Ended<br><br>June 30, 2024	Six-Month Ended<br><br>June 30, 2025	% 2024<br><br>Change
Net cash flows used in operating activities ............................................	(85,175)	(66,618)	(22)%
Net cash flows provided by investing activities ...................................	13,458	1,269	(91)%
Net cash flows provided by (used in) financing activities .....................	40,322	(16,604)	(141)%
Effect of movements in exchange rates on cash held ............................	1,770	(1,785)	(201)%
Revaluation of cash equivalents measured at fair value ........................	—	462	—%
Net increase (decrease) in cash and cash equivalents  .....................	(29,625)	(83,275)	181%
		—
Cash and cash equivalents at the beginning of the period ...............	251,942	144,221	(43)%
Cash and cash equivalents at the end of the period ..........................	222,317	60,946	(73)%

15

Operating Activities

For the six months ended June 30, 2025, cash used in operating activities was €66.6 million, as compared to

€85.2 millionfor the six months ended June 30, 2024, a decrease of €18.6 million, or (22)%. Net cash used in both

periods was predominantly related to payments for the progression of our UC and CD trials, personnel, legal,

professional and infrastructure costs associated with operating as a dual-listed public company. The decrease was

mostly driven by changes in working capital requirements, from €(13.0) million for the six months ended June 30,

2024 to €15.5 million in 2025.

Investing Activities

For the six months ended June 30, 2025, cash provided by investing activities was €1.3 million and was

mainly due to interest received of €1.2 million.

For six months ended June 30, 2024, cash provided by investing activities was €13.5 million and was mainly

due to a decrease in short-term investments of €9.1 million from the payment of the Group's 6-month term deposit

and interest received of €4.8 million.

Financing Activities

For the six months ended June 30, 2025, cash used in financing activities was €16.6 million, which consisted

of repayments of €12.6 million (of which €9.1 million under the tranches A, B and C of the Kreos / Claret

Financing, €2.2 million under the Heights convertible notes and €1.2 million under the PGE) and interest payments

of €3.9 million.

For the six months ended June 30, 2024, cash provided by financing activities was €40.3 million, which

consisted of drawdowns on tranche B (in an amount of €25 million) and tranche C (in an amount of €25 million) of

the senior secured non-convertible bonds from the Kreos / Claret Financing, net of disbursed transaction costs and

deposits (in an amount of €2.6 million in the aggregate), partially offset by repayments of €6.0 million (of which

€4.4 million under the Heights convertible notes) and interest payments of €2.95 million.

Material Cash Requirements

Contractual Obligations and Loans

The following table sets forth aggregate information about material contractual obligations as of June 30,

2025.

The commitment amounts in the table below are associated with contracts that are enforceable and legally

binding and that specify all significant terms, including fixed or minimum services to be used, fixed, minimum or

variable price provisions, and the approximate timing of the actions under the contracts. Future events could cause

actual payments to differ from these estimates. All amounts except the retirement benefits in the table below are

presented gross and are undiscounted.

	As of June 30, 2025	As of June 30, 2025	As of June 30, 2025
	Less than	More than
(In thousands of euros)	1 year	1 year	Total
Financial debt obligations ..........................	36,278	65,017	101,294
Lease obligations .......................................	979	1,012	1,991
Retirements benefits ..................................	0	756	756
Off-balance sheet obligations ....................	215,046	0	215,046
Total ..........................................................	252,303	66,785	319,087

In the ordinary course of our business, we regularly use the services of subcontractors and enter into research

and partnership arrangements with various CROs and with public-sector partners or subcontractors who conduct

clinical trials and studies in relation to the drug candidates. Off-balance sheet obligations in the table above are

16

commitments related to these research and partnership agreements. They are classified at less than one year maturity

in the absence of a fixed schedule in contracts, in case of multiple-year contracts, such as CRO contracts. CRO

contracts include payments that are conditional to the completion of future development milestones. The majority of

the commitments with our CROs are cancellable under certain circumstances such as insolvency, study put on hold

by competent authorities, breach in regulations or negligence in the provision of the services.

Our material cash requirements in the above table do not include potential future royalty payments related to

the royalty certificates, amounting to 2% of the future net sales of obefazimod (worldwide and for all indications).

The amount of royalties that may be paid under the royalty certificates is capped at €172.0 million in the aggregate.

Royalty payments are expected to take place before the expiry date of the certificates, which is 15 years after their

issuance date (September 2, 2037).

As of June 30, 2025, our contractual obligations and loans were

€319.1

million, comprising financial debt

obligations of

€101.3

million (in turn, comprising €45.7 million with respect to the second and third tranches of

senior secured non-convertible bonds in the Kreos / Claret Financing, €24.8 million with respect to Heights

Convertible Notes, €29.5 million with respect of the Kreos / Claret OCABSA and €1.3 million with respect to the

PGE

) and off-balance sheet obligations of

€215.0

million with respect to purchase obligations.

Following the conversion of all the Heights Convertible Notes and the Kreos / Claret OCABSA in July

2025 and August 2025, financial debt obligations amounting to €54.3 million as of June 30, 2025 were extinct.

F-1

INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Condensed Consolidated Statements of Financial Position ...............................................................	F-2
Condensed Consolidated Statements of Loss ....................................................................................	F-3
Condensed Consolidated Statements of Comprehensive Loss ..........................................................	F-4
Condensed Consolidated Statements of Changes in Shareholders’ Equity .......................................	F-5
Condensed Consolidated Statements of Cash Flows .........................................................................	F-6
Notes to the Condensed Consolidated Financial Statements .............................................................	F-7

F-2

ABIVAX SA UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL

POSITION

(Amounts in thousands of euros)	Notes	AS OF<br><br>DECEMBER 31, 2024	AS OF<br><br>JUNE 30, 2025
ASSETS
Non-current assets
Goodwill	6	18,419	18,419
Intangible assets	7	6,606	6,606
Property, plant and equipment	8	2,666	2,159
Other financial assets	9	5,919	5,551
Other receivables and assets	10	948	804
Total non-current assets		34,558	33,539
Current assets
Other financial assets	9	7,554	8,018
Other receivables and assets	10	18,896	17,138
Cash and cash equivalents	11	144,221	60,946
Total current assets		170,671	86,102
TOTAL ASSETS		205,228	119,641
LIABILITIES AND SHAREHOLDERS' EQUITY
Shareholders’ equity
Share capital		633	635
Premiums related to share capital		478,905	479,204
Translation reserve		(75)	484
Retained earnings		(262,637)	(427,819)
Net loss for the period		(176,242)	(100,784)
Total shareholders’ equity	13	40,584	(48,280)
Non-current liabilities
Retirement benefit obligations	16	756	805
Provisions	14	819	1,261
Borrowings	15	29,056	17,896
Convertible loan notes	15	23,370	17,833
Derivative instruments	15	3,620	3,639
Royalty certificates	15	13,023	14,135
Total non-current liabilities		70,645	55,570
Current liabilities
Borrowings	15	22,195	24,641
Convertible loan notes	15	21,574	24,203
Derivative instruments	15	1,166	1,557
Provisions	14	532	1,226
Trade payables and other current liabilities	17.1	43,824	57,497
Tax and employee-related payables	17.2	4,709	3,228
Total current liabilities		93,999	112,352
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		205,228	119,641

F-3

ABIVAX SA UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF LOSS

(Amounts in thousands of euros, except per<br><br>share amounts)	Notes	FOR THE<br><br>THREE<br><br>MONTHS<br><br>ENDED JUNE<br><br>30, 2024	FOR THE<br><br>THREE<br><br>MONTHS<br><br>ENDED JUNE<br><br>30, 2025	FOR THE SIX<br><br>MONTHS<br><br>ENDED JUNE<br><br>30, 2024	FOR THE SIX<br><br>MONTHS<br><br>ENDED JUNE<br><br>30, 2025
Other operating income	18	5,628	1,093	6,815	2,087
Total operating income		5,628	1,093	6,815	2,087
Sales and marketing	19.1	(2,252)	(674)	(4,229)	(1,534)
Research and development	19.2	(28,907)	(38,645)	(64,650)	(77,946)
General and administrative	19.3	(9,796)	(8,270)	(17,932)	(16,303)
Total operating expenses		(40,954)	(47,589)	(86,811)	(95,783)
Operating loss		(35,326)	(46,496)	(79,997)	(93,696)
Financial expenses		(7,056)	(5,415)	(9,514)	(10,857)
Financial income		3,612	3,497	7,873	3,769
Financial gain (loss)	21	(3,444)	(1,918)	(1,641)	(7,088)
Net loss before tax		(38,770)	(48,414)	(81,638)	(100,784)
Income tax	22	—	—	—	—
Net loss for the period		(38,771)	(48,414)	(81,638)	(100,784)
Weighted average number of outstanding<br><br>shares used for computing basic/diluted loss<br><br>per share		62,919,401	63,440,023	62,918,529	63,409,688
Basic / diluted loss per share (€/share)	23	(0.62)	(0.76)	(1.30)	(1.59)

F-4

ABIVAX SA UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE

LOSS

(Amounts in thousands of euros)	Notes	FOR THE<br><br>THREE<br><br>MONTHS<br><br>ENDED JUNE<br><br>30, 2024	FOR THE<br><br>THREE<br><br>MONTHS<br><br>ENDED JUNE<br><br>30, 2025	FOR THE SIX<br><br>MONTHS<br><br>ENDED JUNE<br><br>30, 2024	FOR THE SIX<br><br>MONTHS<br><br>ENDED JUNE<br><br>30, 2025
Net loss for the period		(38,771)	(48,414)	(81,638)	(100,784)
Items that will not be reclassified to profit or<br><br>loss		57	(4)	66	36
Actuarial gains and losses on retirement benefit<br><br>obligations	16	57	(4)	66	36
Items that are or may be reclassified<br><br>subsequently to profit or loss		(43)	348	(80)	559
Foreign currency translation differences		(43)	348	(80)	559
Other comprehensive income (loss)		14	344	(14)	594
Total comprehensive income (loss) for the<br><br>period		(38,756)	(48,070)	(81,652)	(100,189)

F-5

ABIVAX SA UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

(In thousands of euros, except number of<br><br>shares)		NUMBER OF<br><br>SHARES<br><br>ISSUED	SHARE<br><br>CAPITAL	PREMIUMS<br><br>RELATED TO<br><br>SHARE<br><br>CAPITAL	TRANSLATION<br><br>RESERVE	RETAINED<br><br>EARNINGS	NET LOSS<br><br>FOR THE<br><br>YEAR	TOTAL<br><br>SHAREHOLDER<br><br>'S EQUITY
AS OF<br><br>JANUARY 1, 2024		62,928,818	629	478,218	112	(135,210)	(147,740)	196,009
Net loss for the period		—	—	—	—	—	(81,638)	(81,638)
Other comprehensive income (loss)	16	—	—	—	(80)	66	—	(14)
Total comprehensive loss for the period		—	—	—	(80)	66	(81,638)	(81,652)
Appropriation of prior period net loss		—	—	—	—	(147,740)	147,740	—
Transaction costs related to capital increase	13.3	—	—	446	—	—	—	446
Issue of share warrants		—	—	200	—	—	—	200
Exercises of other share warrants		4,000	—	45	—	—	—	45
Shares based compensation expense		—	—	—	—	11,421	—	11,421
AS OF<br><br>JUNE 30, 2024	13.1	62,932,818	629	478,909	32	(271,463)	(81,638)	126,470
AS OF<br><br>JANUARY 1, 2025		63,347,837	633	478,905	(75)	(262,637)	(176,242)	40,584
Net loss for the period		—	—	—	—	—	(100,784)	(100,784)
Other comprehensive income (loss)	16	—	—	—	559	36	—	594
Total comprehensive loss for the period		—	—	—	559	36	(100,784)	(100,189)
Appropriation of prior period net loss		—	—	—	—	(176,242)	176,242	—
Issue of share warrants	14	—	—	300	—	—	—	300
Issue of free shares	14	124,096	1	(1)	—	—	—	—
Shares based compensation expense	14	—	—	—	—	11,021	—	11,021
Other		—	—	—	—	4	—	4
AS OF<br><br>JUNE 30, 2025	13.1	63,471,933	635	479,204	484	(427,819)	(100,784)	(48,280)

F-6

ABIVAX SA UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts in thousands of euros)	Notes		FOR THE SIX<br><br>MONTHS<br><br>ENDED JUNE<br><br>30, 2024	FOR THE SIX<br><br>MONTHS<br><br>ENDED JUNE<br><br>30, 2025
Cash flows used in operating activities
Net loss for the period			(81,638)	(100,784)
Ajustments for:
Elimination of amortization of intangibles and depreciation of property, plant and<br><br>equipment			576	524
Elimination of retirement benefit obligations	16		60	71
Elimination of share-based compensation expenses	14		11,421	11,021
(-) Net gain on sale of treasury shares			(39)	—
Interest expenses and other financial expenses	21	$—	7,967	10,375
Financial income	21	$—	(7,359)	(2,029)
Effect of unwinding the discount related to advances			(351)	(362)
Increase/(decrease) in derivatives and liabilities fair value	15		1,429	(929)
Forgiveness of conditional advances	17		(4,140)	—
Other			(57)	35
Cash flows used in operating activities before change in working capital<br><br>requirements			(72,130)	(82,079)
Decrease / (increase) in other receivables and related accounts			4,023	2,287
Increase / (decrease) in trade payables			(17,279)	13,738
Increase / (decrease) in tax and social security liabilities			(13)	(1,314)
Increase / (decrease) in deferred income and other liabilities			224	750
Changes in working capital requirements			(13,045)	15,461
Cash flows used in operating activities			(85,175)	(66,618)
Cash flows provided by (used in) in investing activities
Acquisitions of intangible assets			(3)	—
Acquisitions of property, plant and equipment			(236)	(63)
Advances reimbursed by (made to) CROs	10		—	40
Increase in deposits	9		(232)	(6)
Decrease in deposits	9		9,050	120
Interest received			4,879	1,178
Cash flows provided by (used in) in investing activities			13,458	1,269
Cash flows provided by (used in) financing activities
Transaction costs related to capital increase	13		446	—
Net proceeds from Kreos and Claret (2) 2 bond loans	15.2 & 15.7		48,544	—
Repayments of Kreos and Claret (2) 2 bond loans	15		—	(9,140)
Repayments of convertible loan notes (3)	15		(4,375)	(2,188)
Repayment of PGE	15		(1,250)	(1,250)
Repayments of conditional advances	15		(55)	—
Payments of the lease liabilities	15		(277)	(458)
Interest paid	15		(2,955)	(3,868)
Other			244	300
Cash flows provided by (used in) financing activities			40,322	(16,604)
Effect of movements in exchange rates on cash held	11		1,770	(1,785)
Revaluation of cash equivalents measured at fair value	11 & 21		—	462
Increase (decrease) in cash and cash equivalents			(29,625)	(83,275)
Cash and cash equivalents at the beginning of the year	11		251,942	144,221
Cash and cash equivalents at the end of the year	11		222,317	60,946
Increase (decrease) in cash and cash equivalents			(29,625)	(83,275)

F-7

ABIVAX SA NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note 1. The Group

Note 1.1. Information on the Group and its business

ABIVAX SA (the “Company”) is a société anonyme incorporated under the laws of France on December 4, 2013. Its registered office

is located at 7-11 Boulevard Haussmann—75009 Paris, France. The Company is developing therapeutics designed to harness the

body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.

These unaudited interim condensed consolidated financial statements as of and for the three- and six-month periods ended June 30,

2025 comprise the Company and ABIVAX LLC (the “Subsidiary”), the United States subsidiary of ABIVAX SA, created on March

20, 2023 under the laws of the State of Delaware (together referred to as the “Group”).

The Group has incurred losses since its inception and had shareholders’ equity of €(48,280) thousand as of June 30, 2025. The Group

anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its drug candidates which

are currently under development. Substantial additional financing will be needed by the Group to fund its operations and to

commercially develop its drug candidates, if approved. See note 3.3. Subsequent event.

The Group's future operations are highly dependent on a combination of factors, including: (i) the success of its research and

development activities; (ii) regulatory approval and market acceptance of its proposed future products; (iii) the timely and successful

completion of additional financing and (iv) the development of competitive therapies by other biotechnology and pharmaceutical

companies. As a result, the Group is, and expects to continue to be, in the short to mid-term, financed through the issuance of new

equity or debt instruments.

The Group is focusing its efforts on the following points:

•Continuation of the Phase 3 clinical trial program (ABTECT) for obefazimod in moderately to severely active ulcerative

colitis (“UC”).

•Continuation of the Phase 2b clinical trial (ENHANCE-CD) of obefazimod in Crohn’s disease (“CD”).

•Evaluating oral or injectable combination therapy candidates with obefazimod in UC.

•Selecting a follow-on candidate for obefazimod.

Note 1.2. Date of authorization of issuance

The unaudited interim condensed consolidated financial statements and related notes have been prepared under the responsibility of

management of the Group and were approved and authorized for issuance by the Group’s board of directors on September 4, 2025.

Note 2. Basis of preparation

Except for share data and per share amounts, the unaudited interim condensed consolidated financial statements are presented in

thousands of euros. Amounts are rounded up or down the nearest whole number for the calculation of certain financial data and other

information contained in these accounts. Accordingly, the total amounts presented in certain tables may not be the exact sum of the

preceding figures.

F-8

Statement of compliance

These unaudited interim condensed consolidated financial statements as of June 30, 2025 and for the three- and six-month periods

ended June 30, 2025 and 2024 have been prepared in accordance with IAS 34 “Interim Financial Reporting” as issued by the

International Accounting Standards Board ("IASB") and as adopted by the European Union (EU) and should be read in conjunction

with the latest Group’s annual financial statements for the years ended December 31, 2022, 2023 and 2024, prepared in accordance

with the International Financial Reporting Standards ("IFRS") as issued by IASB and as adopted by the EU.

They do not include all the information required for a complete set of financial statements prepared under IFRS. They do, however,

include selected notes explaining significant events and transactions in order to understand the changes in the Group’s financial

position and performance since the last annual financial statements.

The accounting policies used to prepare these unaudited interim condensed financial statements are identical to those applied by the

Group as of December 31, 2024, except for:

•the texts whose application is compulsory as from January 1, 2025;

•the specific provisions of IAS 34 used in the preparation of the unaudited interim condensed consolidated financial

statements.

The application of the new Amendments to IAS 21 "The Effects of Changes in Foreign Exchange Rates – Lack of Exchangeability" is

mandatory for annual reporting periods beginning on or after January 1, 2025. The Group concluded that these issued accounting

pronouncements are not applicable for the periods presented.

The standards and interpretations not yet mandatory as of June 30, 2025 are the following:

•Amendments to IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures – Amendments to the

Classification and Measurement of Financial Instruments, whose application is for annual reporting periods beginning on or

after January 1, 2026, as approved by the EU on May 28, 2025;

•Amendments to IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures – Contracts Referencing

Nature-dependent Electricity, whose application is for annual reporting periods beginning on or after January 1, 2026, as

approved by the EU on June 30, 2025;

•IFRS 18 Presentation and Disclosure in Financial Statements, whose application is for annual reporting periods beginning on

or after January 1, 2027 (not yet approved by the EU);

•IFRS 19 Subsidiaries without Public Accountability: Disclosures, whose application is for annual reporting periods beginning

on or after January 1, 2027 (not yet approved by the EU), and

•Annual Improvements Volume 11, whose application is for annual reporting periods beginning on or after January 1, 2026, as

approved by the EU on July 9, 2025.

These texts have not been early adopted. The expected impacts are not considered significant, except for IFRS 18, for which the Group

has not completed its assessment to date.

Preparation of the financial statements

The unaudited interim condensed consolidated financial statements of the Group were prepared on a historical cost basis, with the

exception of certain asset and liability categories and in accordance with the provisions set out in IFRS such as employee benefits

measured using the projected unit credit method, the Heights notes (classified under "Convertible loan notes") measured at fair value

and derivative financial instruments measured at fair value.

F-9

Going concern

The Group has incurred substantial operating losses since inception and expects to continue to incur significant operating losses for the

foreseeable future and may never become profitable. For the six-month period ended June 30, 2025, the Group had a net loss of

€100.8 million. In addition, the Group had negative shareholder's equity of €48.3 million as at June 30, 2025 driven by the losses

incurred.

Since inception, the Group has financed its operations through the issuance of ordinary shares with gross aggregate proceeds of

€1,194.7 million, of which €130 million of gross proceeds were from offerings of its ordinary shares on Euronext Paris in February

2023, €223.3 million of gross proceeds were from its offering of ordinary shares in the form of American Depository Shares ("ADS")

on the Nasdaq Global Market as well as ordinary shares in Europe (including France) and countries outside of the United States in a

private placement in October 2023 and €637.5 million of gross proceeds were from the offering of our ordinary shares in the form of

ADS on the Nasdaq Global Market in July 2025 ("the Offering"), bank borrowings and structured loans for €175.0 million,

reimbursements of CIR in an amount of €41.3 million, subsidies received from Bpifrance (including €21.3 million of subsidies and

€1.8 million of conditional advances) and royalty certificates in an amount of €2.9 million.

Based on (a) the Group’s existing cash and cash equivalents of €60.9 million as of June 30, 2025, (b) the gross proceeds from the July

2025 Offering of €637.5 million and (c) the conversion of all 350 Heights convertible notes in July and August 2025 (see Note 3.3.

below), the Group expects, as of the date of issuance of these financial statements, to be able to fund its forecasted cash flow

requirements into the fourth quarter of 2027, allowing it to reach 12 months of expected cash runway following the planned NDA

submission for UC, assuming positive results from its Phase 3 maintenance trial. This takes into account management's assumptions

of continued R&D expenditure related to the continuation of the Phase 3 clinical trials of obefazimod in UC, progression of the Phase

2b clinical trials for CD and the initial stages of the scale up of the commercial organization as the Group prepares for a potential

launch of obefazimod in UC.

Based on the above, these financial statements have been prepared on a going concern basis.

Impact of the Ukraine/Russia Hostilities on the Group

In February 2022, Russia invaded Ukraine. The conflict has already had major implications for the global economy and the rate of

inflation, particularly in relation to the supply of energy, raw materials and food products. It has also caused intense volatility on the

financial markets, something that is still ongoing at the reporting date and has pushed down stock market prices around the world.

Given these developments, the Group has decided not to include Russia and Belarus in its global Phase 3 program for obefazimod in

UC. However, the global scale of this conflict cannot be predicted at this stage. The Group, therefore, cannot rule out an adverse

impact of this conflict on its business, including in terms of access to raw materials, logistics, the performance of clinical studies and

in relation to any future financing the Group may seek.

The long-term safety and efficacy extension of the Phase 2b maintenance trial of obefazimod in moderately to severely active UC is

the Group’s only clinical trial with patients currently enrolled in Ukraine. The Phase 2b 12-month assessment was carried out in all the

Ukrainian patients before the war broke out and these patients are therefore included in the one-year maintenance results that were

reported on April 6, 2022. Ukrainian patients who completed the two-year Phase 2b maintenance trial have been transitioned to the

long-term safety and efficacy trial that is still on-going. The Group also has a few Ukrainian sites active in the western part of Ukraine

in the ABTECT Phase 3 clinical trials. None of these sites are located in the Crimea Region of Ukraine, the so-called Donetsk

People’s Republic, or the so-called Luhansk People’s Republic. The Group continues to monitor developments in the region, but any

instability as a result of the war may have material adverse impacts on these clinical sites, which could negatively impact our Phase 3

clinical trials.

Together with its CROs, the Group is making considerable efforts to ensure the follow-up of patients who are unable to come to the

study centers. Monitoring takes place through a remote monitoring system that was established and used successfully during the

COVID-19 pandemic.

F-10

Note 3. Significant events for the year ended December 31, 2024 and the six-month period ended June 30, 2025 and subsequent

events

Note 3.1. For the year ended December 31, 2024

Changes in management – February-December 2024

On February 7, 2024, the Group announced the appointment of Ana Sharma as Vice President, Global Head of Quality. Ms. Sharma

left the Group in November 2024.

On April 2, 2024, the Group announced the appointment of Camilla Soenderby as Independent Board Member and also a member of

the Appointments and Compensation Committee. Ms. Soenderby replaces Santé Holdings S.R.L., represented by Mr. Paolo Rampulla,

who will continue to contribute to the work of the Board of Directors as an observer alongside Mr. Maurizio PetitBon from Kreos

Capital/Blackrock.

In July 2024, the Group announced the appointment of Sylvie Grégoire as Independent Board Member, Chairman of the Board and

also a member of the Audit Committee. Ms. Grégoire replaces Ms. Brosgart as Director, Mr. de Garidel as Chairman, and Mr. Hong as

member of the Audit Committee. As the Group entered into the final stages of the ABTECT program and prepared to commence the

Phase 2b ENHANCE-CD trial, Dr. Fabio Cataldi was appointed as Chief Medical Officer, taking over from Dr. Sheldon Sloan, MD,

M Bioethics. Additionally, David Zhang, Ph.D joined the Group as Chief Strategy Officer. Dr. Zhang has internal responsibility for

Biometrics, Quality, HEOR and Regulatory. Finally, the Group also announced that Chief Commercial Officer Michael Ferguson has

left the organization to pursue other opportunities.

On November 13, 2024, the Group announced the appointment of Mark Stenhouse as Board Observer & Advisor to the Group.

On December 23, 2024, the Group announced the resignation of Dr. Philippe Pouletty, representative of Truffle Capital, as director of

the Group, effective on December 31, 2024.

Share-based compensation plans – February-September 2024

In February, March, May, July and September 2024, the Group issued seven free-share compensation plans to certain of its officers

and employees, representing a maximum of 1,946,125 shares in the aggregate, the vesting of which is subject to the following service

condition: 50% of the AGAs vest at the end of a two-year period from the allocation date, 25% at the end of a three-year period from

the allocation date and 25% at the end of a four-year period from the allocation date (with the exception of the 20,000 2024-6 AGAs,

whose vesting conditions are set forth in Note 14).

In March 2024, the Group granted its independent Board members the right to subscribe up to

77,820

share warrants (BSA) in the

aggregate, the vesting of which is subject to a service condition of four years, by tranches of 25% each, vested on each anniversary

date. All the BSAs have been subscribed.

The detailed terms and conditions and the accounting treatment of these plans are presented in Note 14 to the annual consolidated

financial statements of the Group as of December 31, 2024 accompanying the Group’s annual report on Form 20-F for the year ended

December 31, 2024 filed with the Securities and Exchange Commission on March 24, 2025 (the “Annual Report”).

Drawdown of Tranches B and C of the Kreos / Claret Financing – March-June 2024

On March 28, 2024 and June 21, 2024, the Group drew down €25 million related to tranche B and €25 million related to tranche C of

senior secured non-convertible bonds from the Kreos / Claret Financing.  These second and third tranches each consist of 25,000,000

senior secured non-convertible bonds with a par value of €1.00 each, that will not be listed on any market.

The detailed characteristics of these bond loans and their accounting treatments are set forth in Note 15.1 to the annual consolidated

financial statements of the Group as of December 31, 2024 accompanying the Group’s Annual Report.

F-11

Bpifrance RNP-VIR and Carena conditional advances – June 2024

In June 2024, the Group and Bpifrance renegotiated the RNP-VIR and CARENA conditional advances:

•Under the RNP-VIR contract, the Group was eligible to receive up to €6.3 million in conditional advances to further develop

methods for the discovery of new molecules for the treatment of viral infectious diseases through the development of the

“Modulation of RNA biogenesis” platform. Between September 2017 and November 2019, the Group had received repayable

conditional advances amounting €4,032 thousands and subsidies amounting to €1,123 thousand in relation to the RNP-VIR

project.

In June 2024, the Group and Bpifrance agreed to terminate the project due to technical failure. Bpifrance claimed the

reimbursement of €1,241 thousand corresponding to overpayments of conditional advances and subsidies (for which the

Group had not incurred the corresponding R&D expenses) and agreed to waive 60% of the remaining advances of

€2,945 thousand and accrued interests, which resulted in a subsidy income of €1,872 thousand in the aggregate (see Note 18).

The outstanding amount was fully repaid by the Group during the last quarter of 2024.

•Under the CARENA agreement, the Group was eligible to receive up to €3,840 thousand to develop a therapeutic HIV

treatment program with ABX464. Between December 2013 and June 2016, the Group had received repayable conditional

advances amounting €2,187.

In June 2024, the Group and Bpifrance agreed to terminate the project due to technical failure. Bpifrance granted an

additional amount of €1,068 thousand payable to the Group to reimburse additional expenses incurred as part of the project,

and agreed to waive 60% of the remaining conditional advance of €3,255 thousand and accrued interests, which resulted in a

subsidy income of €2,251 thousand in the aggregate (see Note 18). The outstanding amount was fully repaid by the Group

during the last quarter of 2024.

Establishment of an At-the-Market ("ATM") Program on Nasdaq - November 2024

On November 19, 2024, the Group announced the implementation of an At-The-Market program (“ATM Program”) allowing the

Group to issue and sell, including with unsolicited investors who have expressed an interest, ordinary shares in the form of ADSs,

each ADS representing one ordinary share, nominal value €0.01 per share, of the Group, with aggregate gross sales proceeds of up to

$150,000 thousand (subject to French regulatory limits and within the limits of the investors’ requests expressed in the context of the

program), from time to time, pursuant to the terms of an equity distribution agreement with Piper Sandler & Co. (“Piper Sandler”),

acting as sales agent. The timing of any issuances in the form of ADSs will depend on a variety of factors. The ATM Program will be

effective until terminated in accordance with the equity distribution agreement or if ADSs representing the maximum gross sales

proceeds have been sold thereunder. To the extent that ADSs are sold pursuant to the ATM Program, the Group currently intends to

use the net proceeds (after deduction of fees and expenses), if any, of sales of ADSs issued under the ATM Program primarily to fund

the research and development of the Group's product candidates, for working capital and general corporate purposes, at its discretion.

A shelf registration statement on Form F-3, including a base prospectus relating to the Group's securities and an equity distribution

agreement prospectus relating to the ATM Program, was filed with the SEC and went into effect during 2024. The base prospectus

provides for the potential sale of ADSs of the Group with aggregate gross sales proceeds of up to $350,000 thousand (including the

$150,000 thousand covered by the equity distribution agreement prospectus) to grant additional flexibility to the Group in connection

with its financing strategy. The specific terms of any securities to be offered pursuant to the base prospectus will be specified in one or

more prospectus supplements to the base prospectus. As of the date of issuance of our Annual Report, the Group has not utilized the

ATM Program.

F-12

Note 3.2. For the six-month period ended June 30, 2025

Share-based compensation plans – January-May 2025

In January 2025, the Group granted its independent Board members, as well as one of its Board Observers and Advisor, the right to

subscribe up to 125,000 share warrants (BSA) in the aggregate, the vesting of which (if subscribed) is subject to a service condition of

four years, by tranches of 25% each, vested on January, 1 of each year.

In February,  March and May 2025, the Group issued six free-share compensation plans to certain of its officers and employees,

representing a maximum of 4,565,727 shares in the aggregate, the vesting of which is subject to the following service condition: 50%

of the AGAs vest at the end of a two-year period from the allocation date, 25% at the end of a three-year period from the allocation

date and 25% at the end of a four-year period from the allocation date (with the exception of the 123,102 2025-2 AGAs, which vest at

the end of a two-year period from the allocation date, and the 50,000 2025-5 AGAs , which vest only upon the the achievement of

milestones related to clinical studies). Moreover, the vesting of almost half of the 4,319,500 2025-1 AGAs is subject to the occurrence

of a tender offer on the securities issued by the Group and resulting in a change of control of the Group before a certain date.

In April 2025, the Group granted to one of its Board members the right to subscribe up to 39,370 share warrants (BSA), the vesting of

which is subject to a service condition of four years, by tranches of 25% each, vested on May 1 of each year. The BSAs were

subscribed in May 2025.

The detailed terms and conditions of these plans are set forth in Note 14.

Change in management – April 2025

On April 22, 2025, the Group announced the appointment of Dominik Höchli, MD to the Board of Directors of Abivax, effective

immediately.

Completion of enrollment for the Phase 3 ABTECT trials in patients with moderately to severely active UC - April 2025

On April 29, 2025, the Group announced the completion of enrollment for the Phase 3 ABTECT trials in patients with moderately to

severely active UC.

Note 3.3. Subsequent events

Publication of positive Phase 3 results from both ABTECT 8-week induction trials investigating obefazimod, in moderate to severely

active UC – July 2025

On July 22, 2025, the Group announced the results of the ABTECT-1 and ABTECT-2 induction trials in patients with moderately to

severely active UC. ABTECT-1 and 2 are global, multicenter, randomized, double-blind, placebo-controlled trials assessing once-

daily oral administration of obefazimod at 25 mg or 50 mg doses in adult patients with moderately to severely active UC. Eligible

participants had inadequate response, loss of response, or intolerance to conventional and/or advanced therapies.  ABTECT-1 and

ABTECT-2 were conducted simultaneously and have enrolled 1,275 patients from over 600 participating clinical trial sites in 36

countries with the intent to satisfy regulatory requirements globally. The ABTECT Program is one of the largest Phase 3 ulcerative

colitis trials ever conducted and includes the largest population of patients with inadequate response to JAK inhibitor therapy.

Results from the ABTECT-1 and ABTECT-2 trials demonstrated that obefazimod met its FDA primary endpoint of clinical remission

at Week 8 in the 50 mg once-daily dose regimens for both trials. Individually, ABTECT-1 showed a placebo-adjusted clinical

remission rate of 19.3% (p<0.0001) and ABTECT-2 demonstrated 13.4% (p=0.0001), each at the 50 mg once-daily dose, with all key

secondary efficacy endpoints being met.

F-13

The 25 mg once-daily dose of obefazimod achieved the FDA primary endpoint of clinical remission at Week 8 in ABTECT-1

demonstrating a placebo-adjusted remission rate of 21.4%. While the 25 mg dose did not achieve statistical significance for this

endpoint in ABTECT-2, it achieved a pooled placebo-adjusted clinical response rate of 28.6%, indicating a strong signal for these

patients to achieve clinical remission with extended treatment in the maintenance trial.

The safety profile of obefazimod remained consistent with prior clinical experience. No new safety signals were observed in either

trial and the treatment was generally well tolerated across both dose groups.

The ABTECT Maintenance Trial (ABX464-107) is ongoing with top-line results expected to report out during the second quarter of

2026. Among the 1,275 patients randomized in the induction trials, 678 achieved clinical response and enrolled into part 1 of the

maintenance trial. The ABTECT program is one of the largest Phase 3 ulcerative colitis trials ever conducted.

Following this announcement and that of its Offering completed on July 28, 2025 (see Completion of a public offering – July 2025

within this section), the Group’s share price increased significantly, from €6.64 as of June 30, 2025, to €57.00 as of July 28, 2025.

At the same time, the Group reassessed the probability of success (“POS”) of obtaining a future market authorization for obefazimod

in UC, to reflect a reduced level of uncertainty following positive Phase 3 results.

The Group determined that these changes were non-adjusting subsequent events, which as such do not have any impact on the

financial position and the net loss of the Group as of June 30, 2025. These changes, however, are expected to have material effects on

the financial statements to be issued by the Group in future periods.

The estimated financial effects of this event on the Group’s financial statements are the following:

•A significant increase in the carrying value of the royalty certificates, measured at amortized cost, reflecting an increase in the

projected probability-weighted cash flows of the instrument, following the reassessment of the POS,

•Significant changes in the carrying value of the Group’s financial liabilities measured at fair value through profit or loss, i.e.

the Kreos / Claret BSA, the Kreos / Claret MRI and the Heights convertible notes (the latter as well as the Kreos / Claret BSA

being converted into ordinary shares at the request of the noteholders in July and August 2025, see Conversion of the Heights

convertible notes, Kreos / Claret OCABSA and Kreos / Claret BSA – July-August 2025 below),

•Significant changes in the disclosure of the fair values of other financial instruments measured at amortized cost (i.e. the

royalty certificates, the debt components of (i) the Kreos / Claret OCABSA (Tranche A, converted into shares in August

2025) and (ii) Tranche B and C bond loans, as well as the CRO advances; these fair value changes are not expected directly

to impact the future financial position and net loss of the Group).

Conversion of the Heights convertible notes, Kreos / Claret OCABSA and Kreos / Claret BSA – July-August 2025

On July 23 and July 30, 2025, the Group received notices from entities affiliated with Heights Capital Management, which hold

amortizing senior convertible notes of the Group issued in August 2023 (the “Height convertible notes”), for the immediate conversion

of respectively 150 and 200 convertible notes (corresponding to the entirety of the oustanding principal amount of €21.9 million) into

920 377 new ordinary shares of the Group at a conversion price of €23.7674 per ordinary share in accordance with the terms and

conditions of the convertible notes.

On August 6, 2025, Kreos Capital VII(UK) Limited converted the Tranche A portion of the Kreos / Claret Financing (the Kreos /

Claret OCABSA), resulting in the issuance of 785,389 ordinary shares.  In addition, on the same date Kreos Capital VII Aggregator

SCSp exercised its share warrants (the tranche A-B BSA and tranche C BSA) resulting in the issuance of 319,251 ordinary shares of

the Group.

On August 28, 2025, Claret European Growth Capital Fund III SCSp, exercised its share warrants (the tranche A-B BSA and tranche

C BSA) resulting in the issuance of respectively 319,251 and 206,662 ordinary shares of the Group.

F-14

Completion of a public offering – July 2025

On July 28, 2025, the Group announced the completion of an underwritten public offering of 11,679,400 ADSs (the “Offering”), at a

price of $64.00 per ADS (corresponding to €54.58 per ordinary share, based on the exchange rate of €1.00 = $1.1726 as published by

the European Central Bank on July 23, 2025). The aggregate gross proceeds amount to approximately $747.5 million, equivalent to

approximately €637.5 million , before deduction of underwriting commissions and estimated expenses, and the estimated net proceeds,

after deducting underwriting commissions and estimated offering expenses, are approximately $700.3 million, equivalent to

approximately €597.2 million.

The Group believes that the net proceeds from the Offering, together with its current cash and cash equivalents, will allow it to finance

its operations into the fourth quarter of 2027, allowing it to reach 12 months of expected cash runway following the planned NDA

submission for UC, assuming positive results from its Phase 3 maintenance trial (see Note 2 above "Going concern").

F-15

Note 4. Accounting principles

The Group's accounting policies are the same as those described in the annual consolidated financial statements of the Group as of

December 31, 2024 accompanying the Annual Report.

Use of judgments and estimates

In preparing these unaudited condensed consolidated financial statements, management has made judgments and estimates that affect

the application of the Group’s accounting policies and the reported amounts of assets and liabilities, income and expenses. Actual

values may differ from estimated values.

The significant judgments made by management in the application of the Group’s accounting policies and the key sources of

estimation uncertainty are the same as those described in the annual consolidated financial statements of the Group as of December 31,

2024 accompanying the Annual Report.

Measurement of fair values

A number of the Group’s accounting policies require the measurement of fair values, for both financial and non-financial assets and

liabilities.

When measuring the fair value of an asset or a liability, the Group uses market observable data as far as possible. Fair values are

categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows.

•Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.

•Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly

(i.e., prices) or indirectly (i.e., derived from prices).

•Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

Seasonality of operations

The Group’s operations are not subject to significant seasonality.

Note 5. Segment information

The assessment of the Group’s performance and the decisions about resources to be allocated are made by the chief operating decision

maker, based on the management reporting system of the Group. The Group identified the Chief Executive Officer of the Group as

“Chief operating decision maker”. The Chief operating decision maker reviews on an aggregated basis the incurred expenses for

allocating and evaluating performance of the Group.

The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.

Substantially all operations, assets, liabilities, and losses of the Group are located in France. As of June 30, 2025, the Subsidiary’s

contributions to the Group’s assets, liabilities and net losses were less than 10%.

F-16

Note 6. Goodwill and impairment test

Goodwill relates to the acquisition of Splicos SAS that occurred in 2014 (i.e., prior to the transition date to IFRS) which was merged

into the Group the same year.

Goodwill from the Splicos SAS acquisition corresponds to the “Modulation of RNA biogenesis / splicing” technological platform,

from which derived the lead drug candidate of the Group: ABX464.

In accordance with IAS 36, goodwill is allocated to groups of cash generating units (CGUs) at a level corresponding to the lead drug

candidates. Thus, goodwill from Splicos SAS is allocated to the ABX464 CGU.

The net carrying amount of Splicos SAS goodwill is €18,419 thousand as of December 31, 2024 and June 30, 2025.

The ABX464 product candidate being currently in development, a clinical trial failure or a failure to obtain a marketing approval

could result in an impairment. As of June 30, 2025, the Group has not identified any indication of impairment loss related to goodwill,

intangible or tangible assets.

Note 7. Intangible assets

Intangible assets are mainly comprised of the intellectual property underlying:

(i)The collaboration and license agreement with the CNRS, Montpellier 2 University and the Curie for which the Group

paid a milestone of €40 thousand in September 2019 as a result of the entry in phase 2 of ABX464.

(ii)Patents acquired through the acquisition of Prosynergia of €6,529 thousand. The patents are not yet amortized, similarly

to licenses, and are included in the ABX464 CGU for impairment test purposes.

Licenses and patents recognized as Intangible assets are not amortized since they are not operating in a manner intended by the

management. As a consequence, and in accordance with IAS 36, those assets were subject to an annual impairment test as of

December 31, 2024, which did not result in any impairment loss. As of June 30, 2025, no indicator of impairment has been identified.

F-17

(amounts in thousands of euros)	LICENCES	SOFTWARES	PATENTS	OTHER<br><br>INTANGIBLE<br><br>ASSETS	TOTAL
GROSS VALUES
AS OF<br><br>JANUARY 1, 2024	120	24	6,529	—	6,673
Acquisition	—	3	—	—	3
Disposal	—	—	—	—	—
AS OF<br><br>JUNE 30, 2024	120	27	6,529	—	6,677
GROSS VALUES
AS OF<br><br>DECEMBER 31, 2024	120	27	6,529	—	6,677
Acquisition	—	—	—	—	—
Disposal	—	—	—	—	—
AS OF<br><br>JUNE 30, 2025	120	27	6,529	—	6,677		(amounts in thousands of euros)	LICENCES	SOFTWARES	PATENTS	OTHER<br><br>INTANGIBLE<br><br>ASSETS	TOTAL
---	---	---	---	---	---
AMORTIZATION
AS OF<br><br>JANUARY 1, 2024	(45)	(24)	—	—	(70)
Increase	—	—	—	—	—
Disposal	—	—	—	—	—
AS OF<br><br>JUNE 30, 2024	(45)	(24)	—	—	(70)
AS OF<br><br>DECEMBER 31, 2024	(45)	(25)	—	—	(70)
Increase	—	(1)	—	—	(1)
Disposal	—	—	—	—	—
AS OF<br><br>JUNE 30, 2025	(45)	(25)	—	—	(71)		(amounts in thousands of euros)	LICENCES	SOFTWARES	PATENTS	OTHER<br><br>INTANGIBLE<br><br>ASSETS	TOTAL
---	---	---	---	---	---
NET BOOK VALUES
AS OF<br><br>JUNE 30, 2024	75	3	6,529	—	6,607
AS OF<br><br>DECEMBER 31, 2024	75	3	6,529	—	6,606
AS OF<br><br>JUNE 30, 2025	75	2	6,529	—	6,606

F-18

Note 8. Property, plant and equipment

The following tables present changes in property, plant and equipment including the right of use of assets (or “ROU”) as of June 30,

2024 and 2025:

(amounts in thousands of euros)	BUILDINGS		EQUIPMENT		FURNITURE<br><br>AND<br><br>COMPUTER<br><br>EQUIPMENT		TOTAL		OF WHICH<br><br>ROU
GROSS VALUES
AS OF<br><br>JANUARY 1, 2024	1,346	—	513		507		2,366		1,262
Acquisition	2,018		—		241		2,258		2,018
Disposal	(1,110)		0		(104)		(1,214)		(960)
Effect of the change in foreign currency exchange rates	9		—		2		11		9
AS OF<br><br>JUNE 30, 2024	2,263	—	513	—	646	0	3,421	0	2,328
AS OF<br><br>DECEMBER 31, 2024	2,818	—	513		698		4,029		2,526
Acquisition	80		—		26		106		52
Disposal	—		(16)		(39)		(54)		(20)
Effect of the change in foreign currency exchange rates	(49)		—		(11)		(61)		(49)
AS OF<br><br>JUNE 30, 2025	2,849	—	497	—	673	0	4,020	0	2,508		(amounts in thousands of euros)	BUILDINGS		EQUIPMENT		FURNITURE<br><br>AND<br><br>COMPUTER<br><br>EQUIPMENT		TOTAL	OF WHICH<br><br>ROU
---	---	---	---	---	---	---	---	---
DEPRECIATION
AS OF<br><br>JANUARY 1, 2024	(837)		(387)		(265)		(1,488)	(761)
Increase	(456)		(18)		(101)		(575)	(405)
Disposal	1,111				104		1,215	960
AS OF<br><br>JUNE 30, 2024	(182)		(405)		(262)		(849)	(206)
AS OF<br><br>DECEMBER 31, 2024	(613)		(419)		(332)		(1,363)	(575)
Increase	(452)		(19)		(102)		(573)	(422)
Disposal	—		16		39		54	20
Effect of the change in foreign currency exchange rates	16		—		5		21	16
AS OF<br><br>JUNE 30, 2025	(1,048)	—	(422)	—	(390)	0	(1,860)	(961)

F-19

(amounts in thousands of euros)	BUILDINGS		EQUIPMENT		FURNITURE<br><br>AND<br><br>COMPUTER<br><br>EQUIPMENT		TOTAL		OF WHICH<br><br>ROU
NET BOOK VALUES
AS OF<br><br>JUNE 30, 2024	2,081	—	108	—	384	0	2,573	—	2,122
AS OF<br><br>DECEMBER 31, 2024	2,205		94		366		2,666		1,950
AS OF<br><br>JUNE 30, 2025	1,801	—	75	—	283	0	2,159	—	1,547

Right of use assets relate to buildings, vehicles and furniture. The net book value of right of use assets related to buildings amounted to

€2,081 thousand as of June 30, 2024 and €1,489 thousand as of June 30, 2025.

As of June 30, 2025, no indicator of impairment has been identified.

Note 9. Other financial assets

Other financial assets break down as follows:

(amounts in thousands of euros)	AS OF<br><br>DECEMBER 31,<br><br>2024	AS OF<br><br>JUNE 30, 2025
OTHER FINANCIAL ASSETS
Advances related to CRO contracts	4,929	4,603
Deposits	863	822
Other	126	126
Total other non-current financial assets	5,919	5,551
Advances related to CRO contracts	7,418	8,018
Deposits	136	—
Total other current financial assets	7,554	8,018
Other financial assets	13,473	13,569

Advances related to CRO contracts

These advances granted in 2022 for clinical studies are to be recovered at the end of the studies after final reconciliation with pass-

through costs, which are being invoiced and paid as studies are carried out. These long-term advances were measured at fair value on

initial recognition, using discount rates ranging from 0.19% to 7.16%, and are subsequently measured at amortized cost. The recovery

dates of the first two advances are scheduled in the second half of 2025.

During the first half of 2023, additional advances related to CRO contracts amounting to €1,620 thousand were made (undiscounted

amount). These long-term advances were measured at fair value on initial recognition, using discount rates ranging from 7.09% to

7.59%, and are subsequently measured at amortized cost.

At inception, a prepaid expenses asset was recognized for the difference between the advances’ nominal value and fair value, and

spread over the term of the advances, at the rate of recognition of the related R&D expenses (see Note 10).

In March 2024, a change order was signed with the CRO, extending the scope (addition of maintenance studies) and end date of one of

the studies to 2029, thus postponing the recovery date of the corresponding advance of €5,538 thousand from June 2026 to June 2029.

The Group considered that this asset modification met the criteria for derecognition, and recognized a new financial asset at fair value

on that date, using a discount rate of 6.83%. Since the Group considers that these advances are made in exchange for a discount on

future services to be received from the CROs, a prepaid expense asset was also recognized for the difference between the

derecognized asset carrying value and new asset fair value, and spread over the term of the advance in a similar manner.

F-20

The credit risk related to these advances is deemed insignificant due to the CROs' credit ratings.

Deposits

Deposits include the Paris and Boston offices lease contracts, the ATM Program, as well as other security deposits.

Note 10. Other receivables and assets

Other receivables and assets break down as follows:

(amounts in thousands of euros)	AS OF<br><br>DECEMBER 31,<br><br>2024	AS OF<br><br>JUNE 30, 2025
OTHER RECEIVABLES AND ASSETS
Prepaid expenses - non current	948	804
Total non-current other receivables and assets	948	804
Research tax credit ("CIR")	5,774	2,152
VAT receivables	9,841	12,517
Prepaid expenses	3,233	2,331
Credit notes	48	68
Other	—	70
Total current other receivables and assets	18,896	17,138
Other receivables and assets	19,843	17,942

Research tax credit (“CIR”)

The CIR is recognized as Other Operating Income in the year to which the eligible research expense relates. The Group received the

payment for the CIR for the 2024 tax year of €5,640 thousand in June 2025. The additional CIR of €2,152 thousand recorded over the

six-month period ended June 30, 2025 relates to research expenses incurred during the period.

Prepaid expenses

Prepaid expenses as of June 30, 2025 include prepaid expenses related to CRO contracts for an amount of €1,332 thousand (see Note

9) and other expenses from various suppliers amounting to €1,803 thousand.

F-21

Note 11. Cash and cash equivalents

Cash and cash equivalents break down as follows:

(amounts in thousands of euros)	AS OF<br><br>DECEMBER 31,<br><br>2024	AS OF<br><br>JUNE 30, 2025
CASH AND CASH EQUIVALENTS
Cash equivalents	87,265	44,302
Cash	56,956	16,644
Cash and cash equivalents	144,221	60,946

Cash equivalents mainly include term deposits with short-term maturities and highly liquid investments in mutual funds as of

December 31, 2024 and June 30, 2025.

As of December 31, 2024 and June 30, 2025, in addition to the Group’s bank accounts, cash includes notice accounts amounting to

€44,239 thousand and €12,707 thousand respectively. These funds are available on demand within 24 hours and without penalty.

As of December 31, 2024 and June 30, 2025, the impact of the revaluation of cash and cash equivalents held in U.S. dollars into the

Group's presentation currency is a net financial gain of €2,035 thousand and a net financial loss of €1,083 thousand, respectively.

F-22

Note 12. Financial assets and liabilities

The following table shows the carrying amounts and fair value of financial assets and financial liabilities, including their

levels in the fair value hierarchy.

Tax and employee-related payables are non-financial liabilities and are therefore excluded from the tables below. They are

presented in Note 17.2.

			AS OF<br><br>DECEMBER 31,<br><br>2024
(amounts in thousands of euros)	AMOUNT<br><br>RECOGNIZED<br><br>IN THE<br><br>STATEMENT<br><br>OF FINANCIAL<br><br>POSITION	FAIR VALUE	ASSETS/<br><br>LIABILITIES AT<br><br>FAIR VALUE<br><br>THROUGH<br><br>PROFIT AND<br><br>LOSS	ASSETS AT<br><br>AMORTIZED<br><br>COST	LIABILITIES<br><br>AT AMORTIZED<br><br>COST
Other financial assets (2)	13,473	12,690	—	12,690	—
Other receivables and assets (2)	19,843	19,843	—	19,843	—
Cash and cash equivalents (1)	144,221	144,221	—	144,221	—
Total financial assets	177,537	176,754	—	176,754	—
Financial liabilities—non-current portion (4, Note 15)	69,069	73,497	3,620	—	69,877
Financial liabilities—current portion (3, Note 15)	44,935	44,935	21,183	—	23,752
Trade payables and other current liabilities (3)	43,824	43,824	—	—	43,824
Total financial liabilities	157,828	162,256	24,803	—	137,453						AS OF<br><br>JUNE 30, 2025
---	---	---	---	---	---	---
(amounts in thousands of euros)	AMOUNT<br><br>RECOGNIZED<br><br>IN THE<br><br>STATEMENT<br><br>OF FINANCIAL<br><br>POSITION		FAIR VALUE	ASSETS/<br><br>LIABILITIES AT<br><br>FAIR VALUE<br><br>THROUGH<br><br>PROFIT AND<br><br>LOSS	ASSETS AT<br><br>AMORTIZED<br><br>COST	LIABILITIES<br><br>AT AMORTIZED<br><br>COST
Other financial assets (2)	13,569		13,088	—	13,088	—
Other receivables and assets (2)	17,942		17,942	—	17,942	—
Cash and cash equivalents (1)	60,946		60,946	40,462	20,484	—
Total financial assets	92,457		91,976	40,462	51,514	—
Financial liabilities—non-current portion (4, Note 15)	53,503	(50,401)	52,169	3,639	—	48,530
Financial liabilities—current portion (3, Note 15)	50,401		50,401	18,038	—	32,363
Trade payables and other current liabilities (3)	57,497		57,497	—	—	57,497
Total financial liabilities	161,402		160,067	21,677	—	138,390

(1)    The fair value of cash and cash equivalents is determined based on Level 1 fair value measurement and corresponds to the

market value of the assets.

(2)    The carrying amount of financial assets measured at amortized cost is deemed to be a reasonable estimate of fair value, except

for the long-term advances made to CROs, whose fair value is determined based on Level 3 fair value measurement and is estimated

based on future cash-flows discounted at market rates, using credit spreads ranging from 104 bp to 218 bp as of December 31, 2024

and 79 bp to 314 bp as of June 30, 2025. As of December 31, 2024 and June 30, 2025, an increase in the credit spread by +100 bp

would result in a decrease in the advances fair value by €236 thousand and €186 thousand respectively.

(3)    The carrying amount of short-term financial liabilities measured at amortized cost was deemed to be a reasonable estimate of

fair value.

F-23

(4)    The fair value of the royalty certificates, Heights convertible notes, Kreos / Claret BSA and Minimum Return Indemnifications

is based on Level 3 fair value measurement and is estimated based on models and assumptions detailed in Note 15. The fair value of

other long-term financial liabilities is determined based on Level 3 fair value measurement and is estimated based on future cash-flows

discounted at market rates, using the following assumptions:

•For the debt components of the Kreos / Claret OCABSA (tranche A) and the tranches B and C of the Kreos / Claret straight

bond loans, a credit spread of 750 bp as of December 31, 2024 and 1,000 bp as of June 30, 2025.

As of December 31, 2024 and June 30, 2025, an increase in the credit spread by +100 bp would result in a decrease in the

Kreos / Claret tranche A (OCABSA), tranches B and C debt components fair value by respectively €538 thousand and

€1,580 thousand respectively.

•For the PGE loan, a credit spread of 900 bp as of December 31, 2024. As of December 31, 2024 an increase in the credit

spread by +100 bp would result in a decrease in the PGE loan fair value by €39 thousand. The PGE being a short-term

liability as of June 30, 2025, its carrying amount measured at amortized cost is deemed to be a reasonable estimate of its fair

value on that date.

Note 13. Shareholders’ equity

Note 13.1. Share capital issued

The Group manages its capital to ensure that it will be able to continue as a going concern while maximizing the return to

shareholders through the optimization of the debt and equity balance.

As of June 30, 2025, the Group’s share capital amounted to €635 thousand divided into 63,471,933 ordinary shares issued with a

par value of €0.01 each, fully paid up, after taking into account the various capital increases that took place since inception.

Share capital does not include founders’ share subscription warrants (“bons de souscription de parts de créateur d’entreprise” or

“BCE”), share subscription warrants (“Bons de souscription d’actions,” or “BSA”) and free shares (“Attributions gratuites d’actions,”

or “AGA”) that have been granted to certain investors or natural persons, both employees and non-employees of the Group, but not yet

exercised.

The Group held none of its own shares as of December 31, 2024 and June 30, 2025.

The number of outstanding ordinary shares was 63,347,837 and 63,471,933 as of December 31, 2024 and June 30, 2025, respectively.

Note 13.2. Change in share capital

The increase in the share capital for the period ended June 30, 2025 relates to the vesting of 124,096 AGAs, resulting in the issuance

of 124,096 ordinary shares with a par value of €0.01 per share (see Note 14).

Distribution of dividends

The Group did not distribute any dividends for any of the periods presented, does not have any present plan to pay any cash dividends

on its equity securities in the foreseeable future and currently intends to retain all available funds and any future earnings to operate

and expand its business.

F-24

Note 14. Share-based payments

The Group has granted BCEs, BSAs and free shares (attributions gratuites d’actions, or “AGAs”). These plans qualify as “equity

settled” under IFRS 2. The Group does not have any obligation to purchase these instruments in the event of departure or if a specific

event does not occur.

BCEs

The following tables summarize the data relating to BCEs:

TYPE	NUMBER<br><br>OF BCEs<br><br>ISSUED	NUMBER<br><br>OF BCE<br><br>OUTSTAND<br><br>ING AS OF<br><br>JANUARY<br><br>1, 2025	NUMBER<br><br>OF ISSUED<br><br>BCEs	NUMBER<br><br>OF LAPSED<br><br>BCEs	NUMBER<br><br>OF<br><br>EXERCISE<br><br>D BCEs	NUMBER<br><br>OF BCEs<br><br>OUTSTAND<br><br>ING	NUMBER<br><br>OF BCEs<br><br>EXERCISA<br><br>BLE	MAXIMUM<br><br>NUMBER OF<br><br>SHARES TO<br><br>BE ISSUED IF<br><br>ALL<br><br>CONDITIONS<br><br>ARE MET
			FOR THE PERIOD ENDED JUNE 30,<br><br>2025			AS OF<br><br>JUNE 30, 2025
Total<br><br>BCEs	496,965	330,179	—	—	—	330,179	245,962	330,179

BSAs

The following tables summarize the data relating to BSAs:

TYPE	Total<br><br>NUMBER<br><br>OF BSAs<br><br>ISSUED	NUMBER<br><br>OF BCAs<br><br>OUTSTAND<br><br>ING AS OF<br><br>JANUARY<br><br>1, 2025	NUMBER<br><br>OF ISSUED<br><br>BSAs		NUMBER<br><br>OF LAPSED<br><br>BSAs	NUMBER<br><br>OF<br><br>EXERCISE<br><br>D  BSAs	NUMBER<br><br>OF BSAs<br><br>OUTSTAND<br><br>ING	NUMBER<br><br>OF BSAs<br><br>EXERCISA<br><br>BLE	MAXIMUM<br><br>NUMBER OF<br><br>SHARES TO<br><br>BE ISSUED IF<br><br>ALL<br><br>CONDITIONS<br><br>ARE MET
			FOR THE PERIOD ENDED JUNE 30,<br><br>2025				AS OF<br><br>JUNE 30, 2025
Total BSAs	486,714	223,944	164,370	—	—	—	388,314	146,124	388,314

BSAs granted in January and April 2025

In January 2025, the Group granted its independent Board members, as well as one of its Board Observers and Advisor, the right to

subscribe up to 125,000 BSAs in the aggregate, the vesting of which (if subscribed) is subject to a service condition of four years, by

tranches of 25% each, vested on January, 1 of each year. Additionally, the BSAs are subject to a vesting acceleration condition in case

F-25

of a tender offer on the securities issued by the Group and resulting in a change of control of the Group. All of the granted BSAs were

subscribed by the beneficiaries in February 2025.

In April 2025, the Group granted to one of its Board members the right to subscribe up to 39,370 BSAs, the vesting of which is subject

to a service condition of four years, by tranches of 25% each, vested on May, 1 of each year. The BSAs were subscribed in May 2025.

The fair value of the BSAs was determined at grant date using the Black Scholes model, with the following assumptions:

TYPE	FAIR VALUE<br><br>OF THE<br><br>UNDERLYING<br><br>SHARE	FAIR VALUE<br><br>OF THE BSA	NUMBER OF<br><br>BSAs	SUBSCRIPTI<br><br>ON PRICE	STRIKE<br><br>PRICE PER<br><br>SHARE	RISK FREE<br><br>RATE	EXPECTED<br><br>MATURITY	VOLATILITY
BSA-2025-1	€6.13	[€3.5-€3.9]	100,000	€2.00	€6.63	4.65%	[5.5-7 years]	60.88%
BSA-2025-2	€6.13	[€3.5-€3.9]	25,000	€2.00	€6.63	4.65%	[5.5-7 years]	60.88%
BSA-2025-3	€6.48	[€3.7-€4.1]	39,370	€1.27	€6.41	3.92%	[5.5-7 years]	60.69%

AGAs

The following tables summarize the data relating to AGAs as well as the assumptions used for the measurement thereof in

accordance with IFRS 2—Share-based Payment:

TYPE		Total NUMBER<br><br>OF AGAs<br><br>ISSUED		NUMBER OF<br><br>AGAs<br><br>OUTSTANDING<br><br>AS OF<br><br>JANUARY 1,<br><br>2025	NUMBER OF<br><br>ISSUED AGAs	NUMBER OF<br><br>LAPSED AGAs		NUMBER OF<br><br>VESTED AGAs		NUMBER OF<br><br>AGAs<br><br>OUTSTANDING
					FOR THE PERIOD ENDED JUNE 30, 2025					AS OF<br><br>JUNE 30, 2025
Total AGAs	0	9,113,148	—	3,388,040	4,565,727	(160,875)	—	(124,096)	—	7,668,796		TYPE	FAIR VALUE OF<br><br>THE<br><br>UNDERLYING<br><br>SHARE	FAIR VALUE OF<br><br>THE AGA	MATURITY	VOLATILITY	RISK FREE RATE
---	---	---	---	---	---
AGA-2025-1	€5.82	€5.82	N/A	N/A	N/A
AGA-2025-2	€5.82	€5.82	N/A	N/A	N/A
AGA-2025-3	€5.82	€5.82	N/A	N/A	N/A
AGA-2025-4	€5.82	€5.82	N/A	N/A	N/A
AGA-2025-5	€6.17	€6.17	N/A	N/A	N/A
AGA-2025-6	€7.36	€7.36	N/A	N/A	N/A

AGAs granted in February, March and May 2025

In February and May 2025, certain of the Group’s officers and employees were allocated respectively 4,319,500 AGAs (AGA plan

2025-1), 123,102 AGAs (AGA plan 2025-2), 17,625 AGAs (AGA plans 2025-3), 30,500 AGAs (AGA plan 2025-4) and 25,000

AGAs (AGA plan 2025-6) in the aggregate, the vesting of which is subject to certain conditions:

•Subject to remaining employed with the Group, each such officer or employee’s AGAs will be vested as follows: (i) 50% at

the end of a two-year period from the allocation date, (ii) 25% at the end of a three-year period from the allocation date and

(iii) 25% at the end of a four-year period from the allocation date (service condition).

•By exception to the above, the vesting of almost half of the 4,319,500 2025-1 AGAs is subject to the occurrence of a tender

offer on the securities issued by the Group and resulting in a change of control of the Group before a certain date, and the

123,102 2025-2 will vest entirely at the end of a two-year period from the allocation date.

F-26

•Additionally, all the remaining 2025-1 AGAs as well as the 2025-2, 2025-3 and 2025-4 AGAs are subject to a vesting

acceleration condition in case of a tender offer on the securities issued by the Group and resulting in a change of control of

the Group.

In March 2025, a Group employee was allocated 50,000 AGAs (AGA plan 2025-5), the vesting of which is subject to the achievement

of certain milestones related to clinical studies and market authorization of ABX464 in UC and CD. These AGAs are also subject to a

vesting acceleration condition in case of a tender offer on the securities issued by the Group and resulting in a change of control of the

Group.

Breakdown of the compensation expenses accounted for the three- and six-month periods ended June 30, 2024 and

2025:

TYPE<br><br>(in thousands of euros)	FOR THE<br><br>THREE<br><br>MONTHS<br><br>ENDED JUNE<br><br>30, 2024	FOR THE<br><br>THREE<br><br>MONTHS<br><br>ENDED JUNE<br><br>30, 2025	FOR THE<br><br>PERIOD<br><br>ENDED JUNE<br><br>30, 2024		FOR THE<br><br>PERIOD<br><br>ENDED JUNE<br><br>30, 2025
BCEs	(28)	—	(56)	—	—
BSAs	(68)	(71)	(68)	—	(137)
AGAs	(5,570)	(6,261)	(11,297)	—	(10,884)
Social taxes related to AGAs	(178)	(667)	(640)	—	(1,350)
Total	(5,845)	(6,998)	(12,061)	—	(12,371)

Provisions for social taxes related to AGAs are classified within the Current and Non-current Provisions line items in the balance

sheet.

F-27

Note 15. Financial liabilities

Financial liabilities break down as follows:

(amounts in thousands of euros)
FINANCIAL LIABILITIES	AS OF<br><br>DECEMBER 31,<br><br>2024	AS OF<br><br>JUNE 30, 2025
Kreos & Claret bond loans	26,373	16,949
Lease liabilities	1,431	947
PGE	1,252	—
Borrowings	29,056	17,896
Kreos & Claret convertible notes (OCABSA)	23,370	17,833
Convertible loan notes	23,370	17,833
Kreos & Claret minimum return indemnifications	3,620	3,639
Derivative instruments	3,620	3,639
Royalty certificates	13,023	14,135
Other financial liabilities	13,023	14,135
Total non-current financial liabilities	69,069	53,503
Kreos & Claret bond loans	20,028	22,473
Lease liabilities	932	929
PGE	1,235	1,238
Borrowings	22,195	24,641
Heights convertible notes	21,574	17,743
Kreos & Claret convertible notes (OCABSA)	—	6,460
Convertible loan notes	21,574	24,203
Kreos & Claret BSA	1,166	1,557
Derivative instruments	1,166	1,557
Total current financial liabilities	44,935	50,401
Total financial liabilities	114,004	103,905

Note 15.1. Structured debt financing with Kreos & Claret subscribed in August 2023 – “Kreos / Claret Financing”

The Kreos / Claret Financing consists of three tranches of €25,000 thousand each in aggregate principal amount (the convertible

OCABSA and the second and third tranches of non-convertible bonds, respectively the "tranches A, B and C") as well as a Minimal

Return Indemnification ("MRI") to the benefit of the bondholders.

In addition to the Kreos / Claret OCABSA, the Group has issued share warrants (the “tranche A-B BSA” and “tranche C BSA”),

giving Kreos and Claret the right to subscribe to up to 214,198 and 405,832 ordinary shares respectively.

The OCABSA are compound instruments, split between (i) a debt component (then measured at amortized cost) and (ii) an equity

component corresponding to the conversion option and the attached OCABSA warrants.

The OCABSA warrants are considered as an embedded component of the bonds rather than a separate stand-alone financial

instrument.

The Kreos / Claret second and third tranches are hybrid instruments, split between (i) debt host contracts accounted for at amortized

cost and (ii) bifurcated embedded derivatives accounted for at fair value through profit and loss, corresponding to the Minimal Return

Indemnifications and the prepayment options (the fair value of the prepayment options being deemed insignificant at issuance and as

of December 31, 2024 and June 30, 2025).

F-28

As the A-B and C warrants (the "Kreos / Claret BSA") are contractually transferable separately from the bonds and are redeemable in

a variable number of ordinary shares of the Group, they are classified as standalone derivative financial liabilities.

The detailed terms and conditions and the accounting treatment of these instruments are presented in Note 15.1 to the annual

consolidated financial statements of the Group as of December 31, 2024 accompanying the Group’s Annual Report.

On August 6, 2025, Kreos Capital VII(UK) Limited converted the Tranche A portion of the Kreos / Claret Financing (the Kreos /

Claret OCABSA), resulting in the issuance of 785,389 ordinary shares.  In addition, on the same date Kreos Capital VII Aggregator

SCSp exercised its share warrants (the tranche A-B BSA and tranche C BSA) resulting in the issuance of 319,251 ordinary shares of

the Group.

On August 28, 2025, Claret European Growth Capital Fund III SCSp, exercised its share warrants (the tranche A-B BSA and tranche

C BSA) 206,662 shares of the Group.

F-29

Measurement of the Kreos / Claret second and third tranches hybrid instruments

At inception, the net cash proceeds reflect the tranches' initial fair values. The fair values of the Minimal Return Indemnifications were

deducted from the initial carrying values of the debt components of each tranche, which were subsequently measured at amortized cost

using the EIR method.

The fair values of the Minimum Return Indemnifications were measured using the following assumptions:

Tranche B Minimum Return Indemnification - Mars 2024	AS OF DECEMBER 31, 2024	AS OF JUNE 30, 2025
Final redemption scenario probability	95%	95%
Minimal return	1.40x	1.40x
Discount rate	8%	16%
Probability-weighted present value of shortfall payment (in<br><br>thousands of €)	2,635 (Final redemption)<br><br>136 (Tender offer)	2,595 (Final redemption)<br><br>133 (Tender offer)
Probability-weighted fair value of tranche A-B warrants with MRI<br><br>(in thousands of €)	104 (Final redemption)	222 (Final redemption)
Probability-weighted fair value of tranche A-B warrants without<br><br>MRI (in thousands of €)	241 (Final redemption)	386 (Final redemption)
Total fair value of MRI (in thousands of €)	2,499 (Final redemption, i.e. a+b-c)<br><br>136 (Tender offer)	2,431 (Final redemption)<br><br>133 (Tender offer)
Fair value of Tranche B MRI (in thousands of €)	2,636	2,564		Tranche C Minimum Return Indemnification - June 2024	AS OF DECEMBER 31, 2024	AS OF JUNE 30, 2025
---	---	---
Final redemption scenario probability	95%	95%
Minimal return	1.30x	1.30x
Discount rate	8%	16%
(a) Probability-weighted present value of shortfall payment (in<br><br>thousands of €)	1,160 (Final redemption)<br><br>43 (Tender offer)	1,245 (Final redemption)<br><br>45 (Tender offer)
(b) Probability-weighted fair value of tranche A-B warrants with<br><br>MRI (in thousands of €)	684 (Final redemption)	927 (Final redemption)
(c) Probability-weighted fair value of tranche A-B warrants without<br><br>MRI (in thousands of €)	903 (Final redemption)	1,142 (Final redemption)
Total fair value of MRI (in thousands of €)	941 (Final redemption, i.e. a+b-c)<br><br>43 (Tender offer)	1,030 (Final redemption)<br><br>45 (Tender offer)
Fair value of Tranche C MRI (in thousands of €)	984	1,075

For the purpose of measuring the fair value of the MRI (shortfall payment), the fair value of the tranche A-B and C BSA was

measured with a Black Scholes model under the Final redemption scenario and with a Monte Carlo model under the Tender offer

scenario.

The increase in the discount rate assumption for the Tranches B and C MRI between December 31, 2024 and June 30, 2025 primarily

reflects changes in market conditions and a higher credit risk.

As of December 31, 2024, using the same assumption with an increase of +1% volatility, €+1 share price, +1% risk-free rate, +10% in

the probability of achieving the Final redemption scenario and +1% discount rate would result in changes of the MRI B and C fair

value by respectively €-1 thousand, €-3 thousand, €-3 thousand, €+3 thousand and €-82 thousand.

As of June 30, 2025, using the same assumption with an increase of +1% volatility, €+1 share price, +1% risk-free rate, +10% in the

probability of achieving the Final redemption scenario and +1% discount rate would result in changes of the MRI B and C fair value

by respectively €1 thousand, €-82 thousand, €-6 thousand, €-6 thousand and €-60 thousand.

F-30

Measurement of the Kreos / Claret tranche A-B-C BSA

The Kreos / Claret tranche A-B and tranche C BSA are measured at fair value using a Black-Scholes valuation model. The model

considers two probability-weighted scenarios, i.e. (i) the 7-year expiry of the BSA and (ii) an earlier exercise upon a tender offer. The

main data and assumptions are the following:

Kreos/Claret Tranche A-B BSA - August 2023	AS OF DECEMBER 31, 2024	AS OF JUNE 30, 2025
Number of outstanding BSA	214,198	214,198
Exercise price per share	18.67	18.67
Ordinary share price	6.76	6.64
Exercise date	19/8/2030 (expiry)<br><br>18/2/2027 (tender offer)	19/8/2030 (expiry)<br><br>18/2/2027 (tender offer)
7-year expiry scenario probability	95%	95%
Volatility	44.3% (expiry)<br><br>44.3% (tender offer)	60.8% (expiry)<br><br>60.8% (tender offer)
Dividend	—%	—%
Risk-free rate	2.9% (expiry)<br><br>2.9% (tender offer)	1.9% (expiry)<br><br>1.9% (tender offer)
Fair value of issued Kreos/Claret Tranche A-B BSA	243	390		Kreos/Claret Tranche C BSA - November 2023	AS OF DECEMBER 31, 2024	AS OF JUNE 30, 2025
---	---	---
Number of outstanding BSA	405,832	405,832
of which, number of conditional BSA	0	0
Exercise price per share	9.86	9.86
Ordinary share price	6.67	6.64
Exercise date	1/11/2030 (expiry)<br><br>18/2/2027 (tender offer)	1/11/2030 (expiry)<br><br>18/2/2027 (tender offer)
7-year expiry scenario probability	95%	95%
Probability of Drawdown of Tranche C credit facility	Drawn on June 21, 2024	Drawn on June 21, 2024
Volatility	44.3% (expiry)<br><br>44.3% (tender offer)	60.8% (expiry)<br><br>60.8% (tender offer)
Dividend	—%	—%
Risk-free rate	2.9% (expiry)<br><br>2.9% (tender offer)	1.9% (expiry)<br><br>1.9% (tender offer)
Fair value of issued Kreos/Claret Tranche A-B BSA	923	1,167

As of December 31, 2024, using the same assumption with an increase of +1% volatility, €+1 share price, +1% risk-free rate and

+10% in the probability of achieving the 7 years expiry scenario would result in an increase of Kreos / Claret A-B and C BSA fair

value by respectively €37 thousand, €350 thousand, €61 thousand and €75 thousand.

As of June 30, 2025, using the same assumption with an increase of +1% volatility, €+1 share price, +1% risk-free rate and +10% in

the probability of achieving the 7-year expiry scenario would result in an increase of Kreos / Claret A-B and C BSA fair value by

respectively €34 thousand, €391 thousand, €50 thousand and €103 thousand.

F-31

Note 15.2.  Heights convertible notes

The Heights convertible notes consists of (i) a host debt instrument and (ii) conversion and settlement options representing embedded

derivatives. The whole instrument is measured at fair value through profit or loss ("FVTPL") at each reporting date.

In application of the Amendments to IAS 1 Presentation of Financial Statements – Classification of Liabilities as Current or Non-

current, and Non-current Liabilities with Covenants, the Heights convertible notes are classified as current financial liabilities.

The fair value of the Heights convertible notes (including the embedded features) has been measured with a Monte Carlo model,

considering two probability-weighted scenarios: (i) a Put Event or Default/Dissolution scenario and (ii) a voluntary conversion at

maturity scenario. The main data and assumptions are the following:

Heights convertible notes - August 2023	AS OF DECEMBER 31, 2024	AS OF JUNE 30, 2025
Number of outstanding notes	350	350
Original principal amount (in thousands of €)	35,000	35,000
Interest rate	6%	6%
Conversion price per share	€23.77	€23.77
Ordinary share price	€6.76	€6.64
Maturity date	24/08/2025 (put event)<br><br>24/08/2027 (HTM/voluntary conversion)	24/08/2026 (put event)<br><br>24/08/2027 (HTM/voluntary conversion)
Held to maturity scenario probability	75%	75%
Initial price limit	€14.43	€14.43
Early redemption amount (put event)	120%	120%
Volatility	50%	50%
Credit spread	25%	25%
Risk-free rate	2.9%	1.9%
Fair value of Heights convertible notes (in<br><br>thousands of €)	20,017	16,481

As of December 31, 2024, using the same assumptions with an increase of +1% volatility, €+1 share price, +1% risk-free rate and

+10% probability of achieving the held to maturity scenario would result in a change in the Heights convertible notes fair value by

respectively €+2 thousand, €+39 thousand, €-219 thousand and €-631 thousand.

As of June 30, 2025, using the same assumptions with an increase of +1% volatility, €+1 share price, +1% risk-free rate and +10%

probability of achieving the held to maturity scenario would result in a change in the Heights convertible notes fair value by

respectively €+6 thousand, €+42 thousand, €-152 thousand and €-237 thousand.

On the limit date for the drawdown of the second tranche of the Heights Financing (i.e. August 4, 2024), the Group had not drawn

down this tranche and has therefore forgone its right to do so in the future.

On July 23 and July 30, 2025, the noteholders requested the conversion of respectively 150 and 200 convertible notes (corresponding

to the entirety of the outstanding principal amount of approximately €21.9 million) into 920,377 new ordinary shares of the Group at a

conversion price of €23.7674 per ordinary share (see Note 3.3 "Conversion of the Heights convertible notes – July-August 2025").

F-32

Note 15.3. State guaranteed loan – “PGE”

The payment of the last installment of the PGE is scheduled in June 2026.

Note 15.4. Lease liabilities

The variations in lease liabilities are set forth below:

(amounts in thousands of euros)	LEASE LIABILITY
AS OF<br><br>DECEMBER 31, 2023	540
(+) Increase	2,036
(-) Decrease	(353)
AS OF<br><br>JUNE 30, 2024	2,223
AS OF<br><br>DECEMBER 31, 2024	2,363
(+) Increase	—
(-) Decrease	(486)
AS OF<br><br>JUNE 30, 2025	1,876

Lease liabilities mainly relate the Group’s former headquarters in Paris, the Boston office entered into in November 2023, the

Montpellier offices entered into in April 2024, the new Paris headquarters entered into in May 2024 and to a lesser extent to vehicles,

parking lots and printers (Note 8).

As of December 31, 2024 and June 30, 2025, the lease liabilities of the Paris headquarters and Boston offices represented 93% and

92.16% of the total lease liability, respectively.

Lease expenses related to contracts for which a lease liability and right of use asset is recognized under IFRS 16 were €309 thousand

and €428 thousand for the six-month periods ended June 30, 2024 and 2025, respectively. They were recognized for (i) €405 thousand

and €362 thousand as Depreciation expenses and (ii) €25 thousand and €36 thousand as Interest expenses, for the six-month periods

ended June 30, 2024 and 2025, respectively.

Lease expenses related to short-term lease contracts and low value assets that are not included in the valuation of the lease liability

amount to €77 thousand, and €175 thousand for the six-month periods ended June 30, 2024 and 2025, respectively.

Note 15.5. Royalty certificates

The royalty certificates are measured at amortized cost using the EIR method.

The fair value of the royalty certificates, calculated using the same model as their initial measurement, amounts to €7,313 thousand as

of December 31, 2024 and €9,417 thousand as of June 30, 2025.

F-33

The fair value of the royalty certificates is based on the net present value of royalties, which depends on assumptions made by the

Group with regards to the probability of success of its studies (“POS”), the commercialization budget of obefazimod (“peak

penetration”) and the Group's WACC. In addition, royalty projections have been adjusted to reflect any difference between the

Group’s value derived from management projections and the Group’s market capitalization.

As of December 31, 2024, using the same assumptions with an increase of +5 points of POS, +5% of peak penetration (best case

scenario), +1% WACC and €+1 share price would result in a change in the royalty certificates fair value by respectively €

+572 thousand, €+1,735 thousand, €-314 thousand and €+1,160 thousand. Using the same assumptions with a decrease of -5% points

of POS, -5% of peak penetration (worst case scenario) and -1% WACC and €-1 share price would result in a change in the royalty

certificates fair value by respectively €-572 thousand, €-2,527 thousand, €+332 thousand and €-1,160 thousand.

As of June 30, 2025, using the same assumptions with an increase of +5 points of POS, +5% of peak penetration (best case scenario),

+1% WACC and €+1 share price would result in a change in the royalty certificates fair value by respectively €+740 thousand, €

+2,201 thousand, €-395 thousand and €+1,326 thousand. Using the same assumptions with a decrease of -5% points of POS, -5% of

peak penetration (worst case scenario) and -1% WACC and €-1 share price would result in a change in the royalty certificates fair

value by respectively €-740 thousand, €-3,182 thousand, €+416 thousand and €-1,326 thousand.

F-34

Note 15.6. Change in financial liabilities

Changes in financial liabilities, excluding derivative instruments, are presented below as of June 30, 2024 and 2025:

(Amounts in thousands of euros)	Kreos/<br><br>Claret<br><br>convertible<br><br>notes<br><br>(OCABSA)	Kreos &<br><br>Claret<br><br>bond<br><br>loans	Heights<br><br>convertibl<br><br>e notes	PGE	Conditional<br><br>advances BPI	Lease<br><br>liabilities	Royalty<br><br>certificates	Total
FINANCIAL LIABILITIES (excluding<br><br>derivatives instruments)
AS OF<br><br>JANUARY 1, 2024	21,643		29,605	3,678	6,771	540	12,229	74,466
Proceeds		47,444	—					47,444
Repayments			(4,375)	(1,250)	(55)	(353)		(6,033)
Interest paid	(1,125)	(829)	(952)	(18)		(25)		(2,949)
Non-cash changes: classification of<br><br>embedded derivatives as separate<br><br>derivative financial instruments		(3,204)						(3,204)
Non-cash changes: (gain)/loss on<br><br>recognition or derecognition			(295)					(295)
Non-cash changes: interest expense<br><br>and other	1,948	1,365	920	34	7	25	1,933	6,232
Non-cash changes: other fair value<br><br>remeasurement			(91)					(91)
Non-cash changes : subsidies					(4,070)	—	—	(4,070)
Non-cash changes : other<br><br>reclassifications					(173)			(173)
Non cash changes: additional leases						2,036		2,036
AS OF<br><br>JUNE 30, 2024	22,466	44,776	24,812	2,444	2,480	2,223	14,162	113,363
(Amounts in thousands of euros)	Kreos/<br><br>Claret<br><br>convertible<br><br>notes<br><br>(OCABSA)	Kreos &<br><br>Claret<br><br>bond<br><br>loans	Heights<br><br>convertibl<br><br>e notes	PGE	Conditional<br><br>advances BPI	Lease<br><br>liabilities	Royalty<br><br>certificates	Total
FINANCIAL LIABILITIES (excluding<br><br>derivatives instruments)
AS OF<br><br>DECEMBER 31, 2024	23,370	46,401	21,574	2,488	—	2,363	13,023	109,218
Repayments		(9,140)	(2,188)	(1,250)		(454)		(13,032)
Interest paid	(1,125)	(1,974)	(689)	(43)		(36)		(3,868)
Non-cash changes: (gain)/loss on<br><br>recognition or derecognition			(295)					(295)
Non-cash changes: interest expense and<br><br>other	2,048	4,136	680	44		36	1,112	8,056
Non-cash changes: other fair value<br><br>remeasurement			(1,339)					(1,339)
Non cash changes : Effect of the change in<br><br>foreign currency exchange rates						(32)		(32)
AS OF<br><br>JUNE 30, 2025	24,293	39,423	17,743	1,238	—	1,876	14,135	98,709

For the six-month period ended June 30, 2024, proceeds from the issuance of the Kreos / Claret tranches B and C bond loans are

presented net of transaction costs and deposits (corresponding to the prepayments of half of the last debt installments on issuance date)

included in the debt discount using the EIR method, and amounting to €1,475 thousand and €1,081 thousand respectively. Net

proceeds from non-convertible bond loans of €48,544 thousand disclosed in the Unaudited Condensed Consolidated Statements of

Cash Flows for the six-month period ended June 30, 2024 do not include transaction fees of (i) €500 thousand related to the Kreos /

Claret tranche A-B warrants classified as prepaid expenses as of December 31, 2023 and €600 thousand related to tranche C and not

yet disbursed as of June 30, 2024.

F-35

Note 15.7. Change in derivative instruments

Changes in derivative instruments are presented below as of June 30, 2024 and 2025:

(amounts in thousands of euros)	Kreos/Claret BSA	Kreos/Claret<br><br>Minimum Return<br><br>Indemnifications	Total
DERIVATIVE FINANCIAL<br><br>INSTRUMENTS
AS OF<br><br>JANUARY 1, 2024	2,579	—	2,579
(+) Issuance	—	2,158	2,158
(+) Increase in fair value	1,542	5	1,547
(-) Decrease in fair value	—	(27)	(27)
AS OF JUNE 30, 2024	4,121	2,136	6,257
AS OF<br><br>JANUARY 1, 2025	1,166	3,620	4,786
(+) Increase in fair value	391	91	482
(-) Decrease in fair value	—	(72)	(72)
AS OF<br><br>JUNE 30, 2025	1,557	3,639	5,196

Details related to these instruments' accounting treatments and terms and conditions are set forth in Notes 15.1 and 15.2 of these

financial statements, as well as in Notes 15.1 and 15.2 to the annual consolidated financial statements of the Group as of December 31,

2024 accompanying the Group’s Annual Report.

Note 15.8. Breakdown of financial liabilities by maturity

The following are the remaining contractual maturities of financial liabilities as of December 31, 2024 and June 30, 2025. The

amounts are gross and undiscounted, and include contractual interest payments.

	AS OF<br><br>DECEMBER 31, 2024
CURRENT AND NON-CURRENT<br><br>FINANCIAL LIABILITIES	GROSS<br><br>AMOUNT	CONTRACTUAL<br><br>CASH FLOWS	LESS THAN 1<br><br>YEAR	FROM 1 TO 2<br><br>YEARS	FROM 2 TO 5<br><br>YEARS	LONGER<br><br>THAN 5<br><br>YEARS
(amounts in thousands of euros)
Heights convertible notes	21,574	24,063	8,750	8,750	6,563	—
Kreos/Claret convertible notes<br><br>(OCABSA)	23,370	30,653	2,250	19,943	8,460	—
Kreos/Claret bond loans	46,401	58,080	24,016	25,715	8,348	—
PGE	2,488	2,586	1,293	1,293	—	—
Royalty certificates	13,023	—	—	—	—	—
Lease liabilities	2,363	2,512	993	996	516	7
Derivative instruments	4,786	4,786	1,166	—	3,620	—
Total financial liabilities	114,004	122,680	38,468	56,698	27,507	7

F-36

	AS OF<br><br>JUNE 30, 2025
CURRENT AND NON-CURRENT<br><br>FINANCIAL LIABILITIES	GROSS<br><br>AMOUNT	CONTRACTUAL<br><br>CASH FLOWS		LESS THAN 1<br><br>YEAR		FROM 1 TO 2<br><br>YEARS		FROM 2 TO 5<br><br>YEARS		LONGER<br><br>THAN 5<br><br>YEARS
(amounts in thousands of euros)
Heights convertible notes	17,743	24,828		1,313		1,313		22,203		—
Kreos/Claret convertible notes<br><br>(OCABSA)	24,293	29,528		8,148		21,380		—		—
Kreos/Claret bond loans	39,423	45,670		25,549		20,121		—		—
PGE	1,238	1,268		1,268		—		—		—
Royalty certificates	14,135	—		—		—		—		—
Lease liabilities	1,876	1,991		979		907		105		—
Derivative instruments	5,196	5,196		1,557		3,639				—
Total financial liabilities	103,905	108,481	$—	38,814	0	47,359	$—	22,308	0	—

(1) The contractual cash flows above do not include potential future royalty payments related to the royalty certificates, amounting to

2% of the future net sales of obefazimod (worldwide and for all indications). The amount of royalties that may be paid under the

royalty certificates is capped at €172.0 million in the aggregate. Royalty payments are expected to take place before the expiry date of

the certificates, which is 15 years after their issuance date (September 2, 2037), and would be included in the "from 2 to 5 years" and

"longer than 5 years" maturity categories according to management's projections.

Note 16. Retirement benefit obligations

Retirement benefit obligations include the liability for the defined benefit plan, measured based on the provisions stipulated

under the applicable collective agreements, i.e. the French pharmaceutical industry’s collective agreement. This commitment

only applies to employees subject to French law. Employees in the U.S. benefit from defined contribution plans (401(k)).

Note 17. Payables and other current liabilities

Note 17.1. Trade payables and other current liabilities

Trade payables and other current liabilities break down as follows:

(amounts in thousands of euros)
TRADE PAYABLES AND OTHER CURRENT LIABILITIES	AS OF<br><br>DECEMBER 31,<br><br>2024		AS OF<br><br>JUNE 30, 2025
Trade payables	30,748		36,114
Accrued invoices	13,049		21,376
Other	26		7
Trade payables and other current liabilities	43,824	—	57,497

The increase in accrued invoices as of June 30, 2025 compared to December 31, 2024 is mainly explained by upcoming

milestones and increased activity on ABTECT reflecting the progress on phase 3 clinical trials.

F-37

Note 17.2. Tax and employee-related payables

Tax and employee-related payables are presented below:

(amounts in thousands of euros)
TAX AND EMPLOYEE-RELATED PAYABLES	AS OF<br><br>DECEMBER 31,<br><br>2024	AS OF<br><br>JUNE 30, 2025
Employee-related payables	2,742	2,184
Social security and other	1,783	881
Other tax and related payments	184	163
Tax and employee-related payables	4,709	3,228

Note 18. Operating income

Operating income is composed as below:

(amounts in thousands of euros)
OPERATING INCOME	FOR THE<br><br>THREE<br><br>MONTHS<br><br>ENDED JUNE<br><br>30, 2024	FOR THE<br><br>THREE<br><br>MONTHS<br><br>ENDED JUNE<br><br>30, 2025	FOR THE SIX<br><br>MONTHS<br><br>ENDED JUNE<br><br>30, 2024	FOR THE SIX<br><br>MONTHS<br><br>ENDED JUNE<br><br>30, 2025
Research tax credit ("CIR")	1,515	1,047	2,665	2,017
Subsidies	4,096	—	4,121	—
Other	18	46	29	70
Total operating income	5,628	1,093	6,815	2,087

Research tax credit (“CIR”)

The Group carries out research and development projects. As such, it has benefited from a research tax credit for the six-month

periods ended June 30, 2024 and 2025 for an amount of €2,665 thousand and €2,017 thousand, respectively.

Subsidies

Subsidies primarily relate to the Bpifrance RNP-VIR and CARENA conditional advances, the repayments of which were partly

waived by Bpifrance in June 2024, for €1,872 thousand and €2,251 thousand respectively (see Note 3.1).

Note 19. Operating expenses

F-38

Note 19.1. Sales and marketing

(amounts in thousands of euros)
SALES AND MARKETING	FOR THE THREE<br><br>MONTHS ENDED<br><br>JUNE 30, 2024	FOR THE THREE<br><br>MONTHS ENDED<br><br>JUNE 30, 2025	FOR THE SIX<br><br>MONTHS<br><br>ENDED JUNE 30,<br><br>2024	FOR THE SIX<br><br>MONTHS<br><br>ENDED JUNE 30,<br><br>2025
Personnel costs	353	474	1,443	944
Consulting and professional fees	1,547	166	2,093	384
Other sales and marketing expenses	352	34	693	206
Sales & Marketing	2,252	674	4,229	1,534

The sales and marketing expenses as of June 30, 2025 consist primarily in consulting costs associated with market research in

preparation for the Group's future sales and commercialization efforts in the U.S. The decrease for the three- and six-month periods

ended June 30, 2025 compared to June 30, 2024 was predominantly driven by a reduction in headcount as well as one-time costs that

were incurred in 2024 for our corporate re-branding, including our new website.

Note 19.2. Research and development

Research and development expenses break down as follows:

(amounts in thousands of euros)
RESEARCH AND DEVELOPMENT<br><br>EXPENSES	FOR THE<br><br>THREE<br><br>MONTHS<br><br>ENDED JUNE<br><br>30, 2024	FOR THE<br><br>THREE<br><br>MONTHS<br><br>ENDED JUNE<br><br>30, 2025	FOR THE SIX<br><br>MONTHS<br><br>ENDED JUNE<br><br>30, 2024	FOR THE SIX<br><br>MONTHS<br><br>ENDED JUNE<br><br>30, 2025
Sub-contracting, studies and research	20,207	30,139	47,282	59,292
Personnel costs	4,868	5,558	9,421	10,627
Consulting and professional fees	2,280	1,867	5,489	5,848
Intellectual property fees	600	238	941	476
Other research and development expenses	952	843	1,519	1,703
Research and development expenses	28,907	38,645	64,650	77,946

For the six-month period ended June 30, 2025, research and development expenses were €77,946 thousand, as compared to

€64,650 thousand for the six-month period ended June 30, 2024, and consisted primarily of expenses related to the UC clinical

program for €51,929 thousand, the CD clinical program for €7,416 thousand, as well as transversal activities for €14,829 thousand.

This increase was primarily due to a €6,499 thousand increase in expenses related to the CD program, resulting from the progression

of the Phase 2b trials in CD and an increase in transversal activities related to the overall expansion of the research and development

headcount to support the Group's organizational growth and the issuance of new equity awards to officers and employees in research

and development. Similar factors have driven the increase for the three-month period ended June 30, 2025 compared to 2024.

F-39

Note 19.3. General and administrative

(amounts in thousands of euros)
GENERAL AND ADMINISTRATIVE<br><br>EXPENSES	FOR THE<br><br>THREE<br><br>MONTHS<br><br>ENDED JUNE<br><br>30, 2024	FOR THE<br><br>THREE<br><br>MONTHS<br><br>ENDED JUNE<br><br>30, 2025	FOR THE SIX<br><br>MONTHS<br><br>ENDED JUNE<br><br>30, 2024	FOR THE SIX<br><br>MONTHS<br><br>ENDED JUNE<br><br>30, 2025
Personnel costs	5,898	5,244	11,172	9,932
Consulting and professional fees	2,331	1,768	3,848	3,703
Other general and administrative expenses	1,566	1,258	2,912	2,668
General and administrative expenses	9,796	8,270	17,932	16,303

For the six-month period ended June 30, 2025, general and administrative expenses were €16,303 thousand, as compared to €17,932

thousand for the six-month period ended June 30, 2024. This decrease was primarily due to a decrease in personnel costs of

€1,240 thousand, or 11%, mainly resulting from the expense recognition pattern of equity awards granted to certain of the Group's

officers and employees, many of which were issued in connection with the Group's U.S. initial public offering and listing on Nasdaq in

October 2023, as well as strict adherence to the approved budget, which includes savings through the gating of non essential spend.

These were partially offset by increased legal and professional fees and other costs associated with operating as a dual-listed public

company. Similar factors have driven the decrease for the three-month periods ended June 30, 2025 compared to 2024.

Note 20. Employees

The Group’s average workforce during the periods ended June 30, 2024 and 2025 was as follows:

HEADCOUNT	FOR THE SIX<br><br>MONTHS ENDED<br><br>JUNE 30, 2024	FOR THE SIX<br><br>MONTHS ENDED<br><br>JUNE 30, 2025
France	34	42
United States	27	27
Total	61	69

F-40

Note 21. Financial gain (loss)

The financial loss breaks down as follows:

(amounts in thousands of euros)
FINANCIAL GAIN (LOSS)	FOR THE THREE<br><br>MONTHS ENDED<br><br>JUNE 30, 2024	FOR THE THREE<br><br>MONTHS ENDED<br><br>JUNE 30, 2025	FOR THE SIX<br><br>MONTHS ENDED<br><br>JUNE 30, 2024	FOR THE SIX<br><br>MONTHS ENDED<br><br>JUNE 30, 2025
Interest on bond loans	(1,365)	(1,981)	(1,365)	(4,136)
Interest on convertible loan notes	(1,431)	(1,372)	(2,868)	(2,728)
Interest on conditional advances and PGE	(10)	(22)	(61)	(44)
Interest on royalty certificates	(1,002)	(129)	(1,933)	(1,112)
Interest on lease liabilities	(20)	(17)	(25)	(36)
Increase in derivatives fair value	(639)	(536)	(1,547)	(482)
Increase (decrease) in other liabilities (assets) at fair<br><br>value through profit and loss	(1,480)	—	—	—
Transaction costs	(1,025)	—	(1,606)	—
Foreign exchange losses	(6)	(1,352)	(76)	(2,306)
Other financial expense	(80)	(7)	(34)	(14)
Financial expenses	(7,056)	(5,415)	(9,514)	(10,857)
Interest income	2,277	190	4,811	1,049
Decrease in derivatives fair value	306	156	27	72
Decrease (increase) in other liabilities (assets) at fair<br><br>value through profit and loss	—	2,765	91	1,801
Effect of unwinding the discount related to advances<br><br>made to CROs	169	129	351	362
Day-one gain on recognition of financial liabilities	147	147	295	295
Foreign exchange gains	713	110	2,298	189
Financial income	3,612	3,497	7,873	3,769
Financial gain (loss)	(3,444)	(1,918)	(1,641)	(7,088)

Interest on bond loans consists of interests from the Kreos / Claret B and C tranches, drawn down in respectively March and June

2024, thus explaining the increase for the three- and six-month periods ended June 30, 2025 compared to 2024 (see Note 15.1).

Interests on convertible loan notes corresponds to interests from the Kreos / Claret OCABSA (tranche A) and from the Height notes

(see Notes 15.1 and 15.2).

Transaction costs for the three- and six-month periods ended June 30, 2024 mainly relate to the amortization of the prepaid expenses

related to the transaction costs of the Kreos / Claret tranche C bond loans (see Note 15.1).

Increases and decreases in the fair value of derivatives for the six-month period ended June 30, 2025 are detailed in Notes 15.1, 15.2

and 15.7.

The decrease and  increase in other liabilities at fair value through profit or loss ("FVTPL") mainly relate to the Heights notes for the

three- and six-month periods ended June 30, 2024 and June 30, 2025 respectively (see Note 15.2). For the three- and six-month

periods ended June 30, 2025, this line item also includes an income of respectively €375 thousand the €462 thousand resulting from

the revaluation of cash equivalents measured at FVTPL.Interest income mainly relates to the invested proceeds from (i) the Group's

initial public offering on the Nasdaq Global Market and the concurrent European Private Placement from October 2023, and (ii) the

F-41

Kreos / Claret and Heights Financings. The decrease in interest income is mainly driven by the decrease in the cash & cash equivalents

position (see Note 11).

Foreign exchange losses for the three- and six-month periods ended June 30, 2025 relate to the translation of cash and cash equivalents

held in U.S. dollars into the Group's presentation currency as of June 30, 2025 , resulting in a loss of €1,083 thousand, and to other

realized and unrealized losses on foreign exchange transactions (see Note 11).

Note 22. Income tax

The Group incurred tax losses in the current period and prior years. As the recoverability of these tax losses is not considered probable

in subsequent periods due to the uncertainties inherent in the Group’s business, the Group has not recognized deferred tax assets

beyond deferred tax liabilities arising within the same taxable entity under the same taxable regime and with consistent timing of

reversal, after considering, if applicable, limitations in the use of deductible tax losses carried forward from prior periods applicable

under tax laws in France and in the U.S.

Note 23. Income (loss) per share

Basic losses per share is calculated by dividing income (loss) attributable to equity holders of the Group by the weighted-

average number of outstanding ordinary shares for the period.

Diluted losses per share are calculated by adjusting the weighted average number of ordinary outstanding shares to assume

conversion of all dilutive potential ordinary shares.

(amounts in thousands of euros, except share data)
BASIC AND DILUTED LOSS PER SHARE	FOR THE<br><br>THREE<br><br>MONTHS<br><br>ENDED JUNE 30,<br><br>2024	FOR THE<br><br>THREE<br><br>MONTHS<br><br>ENDED JUNE 30,<br><br>2025	FOR THE SIX<br><br>MONTHS<br><br>ENDED JUNE 30,<br><br>2024		FOR THE SIX<br><br>MONTHS<br><br>ENDED JUNE 30,<br><br>2025
Weighted average number of outstanding shares	62,919,401	63,440,023	62,918,529	—	63,409,688
Net loss for the period	(38,771)	(48,414)	(81,638)	—	(100,784)
Basic and diluted loss per share (€/share)	(0.62)	(0.76)	(1.30)		(1.59)

Since net results for the three- and six-month periods ended June 30, 2024 and 2025 are losses, potentially dilutive instruments (BCEs,

BSAs, AGAs, the OCABSA, the Kreos / Claret BSAs and the Heights notes) have been excluded from the computation of diluted

weighted-average shares outstanding, because such instruments had an antidilutive impact. Consequently, the diluted losses per share

are the same as the basic losses per share.

Note 24. Related parties

Except for share-based compensation plans (see Note 14), the Group has not engaged in any new transaction with its related parties

over the six-month period ended June 30, 2025.

Note 25. Off-balance sheet commitments given

On December 12, 2024, the Group was notified of a claim from the seller of Prosynergia requesting the payment of an earn-out in

connection with the transaction. Legal proceedings are ongoing in French court. The Group has not recorded any provision in its

financial statements in connection with this claim due to uncertainty in the outcome of this proceeding.

Over the period ended June 30, 2025, the Group has not given any significant additional off-balance sheet commitment or amended

already existing commitments. The off-balance sheet commitments given by the Group as of June 30, 2025 are identical to December

31, 2024, with the exception of the following changes in the commitments related to CRO contracts:

F-42

In the ordinary course of business, the Group regularly uses the services of subcontractors and enters into research and partnership

arrangements with various contract research organizations, or CROs, and with public- sector partners or subcontractors, who conduct

clinical trials and studies in relation to the drug candidates. As of December 31, 2024 and June 30, 2025, the Group’s commitments

amounted to respectively €234,908 thousand and €215,046 thousand. The cost of services performed by CROs is recognized as an

operating expense as incurred.

Note 26. Off-balance sheet commitments received and contingent assets

Over the six-month period ended June 30, 2025, the Group has not received any significant additional commitment and has not

identified any contingent assets susceptible to being recognized in the future.

Note 27. Management and assessment of financial risks

The Group is exposed to interest rate risk, credit risk, foreign currency risk and liquidity risk. The Group has not identified any

significant changes in the identified credit and interest rate risks as of June 30, 2025 compared to December 31, 2024.

Liquidity risk

The remaining contractual maturities of financial liabilities as of December 31, 2024 and June 30, 2025 are presented in Note 15.8.

The Group's estimate of its cash runway as of the date of approval of these financial statements is set forth in Note 2 - Going concern.

Foreign currency risk

The Group is exposed to a risk of exchange rates fluctuations on commercial transactions performed in currencies different from the

functional currency of the Group entity recording the transactions.

For six-month period ended June 30, 2025, expenses in U.S. dollars totaled €7,408 thousand based on the average annual exchange

rate on that date. As a result, an adverse 10% change in the exchange rate for the U.S. dollar against the euro would have resulted in a

foreign exchange rate loss of approximately €823 thousand for the six-month period ended June 30, 2025.

At this stage, the Group has not adopted any other recurring mechanism of hedging to protect its activity against currency fluctuations.

From time to time, the Group may nevertheless subscribe currency term accounts in order to cover a commitment in currency as

described above. The Group may consider in the future using a suitable policy to hedge exchange risks in a more significant manner if

needed.

Document

Abivax Presents First Half 2025 Financial Results

PARIS, France, September 8, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its key financial information for the six months ended June 30, 2025. The interim financial statements for the first half of 2025, approved by the Company’s Board of Directors on September 4, 2025, have been reviewed by the Company’s external auditors.

Abivax provided the following key updates on its business and operational goals in press releases published:

•On June 11, 2025, a press release titled “Abivax Announces Results of its June 6, 2025 Annual General Meeting”

•On July 22, 2025, a press release titled “Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis”

•On July 28, 2025, a press release titled “Abivax Announces Closing of $747.5 Million Public Offering”

First Half 2025 Financial Highlights (IFRS figures)

(Consolidated, unaudited results)

Income Statement	Six months ended<br><br>June 30,		Change
in millions of euros	2025	2024
Total operating income	2.1	6.8	(4.7)
Total operating expenses
of which Research and Development costs	(77.9)	(64.7)	(13.2)
of which Sales and Marketing costs	(1.5)	(4.2)	2.7
of which General and Administrative costs	(16.3)	(17.9)	1.6
Operating loss	(93.7)	(80.0)	(13.7)
Financial (loss)	(7.1)	(1.6)	(5.5)
Net loss for the period	(100.8)	(81.6)	(19.2)
Balance Sheet	June 30, 2025	December 31, 2024	Change
---	---	---	---
in millions of euros
Net financial position	(20.2)	53.4	(73.6)
of which other current financial assets and other current receivables and assets*	22.8	23.2	(0.4)
of which available cash and cash equivalents	60.9	144.2	(83.3)
(of which financial liabilities)**	(103.9)	(114.0)	10.1
Total Assets	119.6	205.2	(85.6)
Total Shareholders’ Equity	(48.3)	40.6	(88.9)
* Excluding items of the liquidity contract (liquidity and own shares) and prepaid expenses<br><br>** Financial liabilities include borrowings, convertible loan notes, derivative instruments, royalty certificates and other financial liabilities

•Operating loss increased by EUR 13.7M to EUR -93.7M for the six months ending June 30, 2025 compared to EUR -80.0M for the six months ending June 30, 2024. Operating income, consisting predominantly of Research Tax Credit and Subsidies, decreased by EUR 4.7M to EUR 2.1M for the six months ending June 30, 2025 compared to EUR 6.8M for the six months ending June 30, 2024. The increase in operating loss was driven by operating expenses as described further below.

•Research and development (R&D) expenses increased by EUR 13.2 to EUR -77.9M in the first half of 2025 compared to EUR -64.7M in the same period 2024. This increase was predominantly driven by expenses related to:

◦A EUR 6.5M, increase related to the Company’s Crohn’s Disease (CD) clinical program, driven by the progression of Phase 2b clinical trials for obefazimod in CD; and

◦A EUR 5.7M increase in transversal personnel expenses related to the overall expansion of the R&D headcount to support the Company’s organizational growth and the issuance of new equity awards to officers and employees in R&D.

◦Expenses related to the Company’s UC clinical program remained relatively stable, increasing by EUR 0.2 million.

•Sales and marketing (S&M) expenses decreased by EUR -2.7M to EUR -1.5M for the six-month period ending June 30, 2025 compared to EUR -4.2M for the same period 2024. The decrease was predominantly driven by a reduction in headcount as well as one-time costs that were incurred in 2024 for the Company's corporate re-branding, including its new website.

•General and administrative (G&A) expenses decreased to EUR -16.3M for the first half of 2025 compared to EUR -17.9M for the first half of 2024. This decrease was primarily due to:

◦A decrease in personnel costs of EUR 1.2M, resulting from the timing of expense recognition in equity awards granted to officers and employees, many of which were issued in connection with the Company’s U.S. initial public offering and listing on Nasdaq in October 2023 as well as strict adherence to the approved budget, which includes savings through reducing non-essential spend;

◦Offset by increased spending related to legal and professional fees and other costs associated with operating as a dual-listed public company.

•For the six-months ended June 30, 2025, the EUR -7.1M net financial loss was driven primarily by the following items:

◦Interest expenses of EUR -6.9M in relation to borrowings and loans; and

◦Non-cash expense of EUR -1.1M in relation to royalty certificates; and

◦Foreign exchange losses of EUR -2.3M;

◦Offset by interest income of EUR 1.1M in relation to the invested proceeds from cash on hand, EUR 1.8M related to the decrease in liabilities at fair value through profit and loss (EUR 1.3M of this relating to the Heights convertible note), and EUR 0.2M of other non-cash financial income.

•Cash position as of June 30, 2025, was EUR 60.9M compared to EUR 144.2M as of December 31, 2024. The decrease was due to EUR -66.6M used in operations and EUR -16.6M related to principal and interest paid on the Comany’s debt facilities. This decrease was offset by EUR 1.2M of interest received on cash.

•On July 28, 2025, Abivax completed its underwritten public offering of 11,679,400 American Depositary Shares, each representing one ordinary share, EUR 0.01 nominal value per share, of the Company, in the United States. The aggregate gross proceeds amounted to approximately $747.5 million, equivalent to approximately EUR 637.5 million, before deduction of underwriting commissions and offering expenses, and the net proceeds, after deducting underwriting commissions and offering expenses, were approximately $700.3 million, equivalent to approximately EUR 597.2 million.

•On July 23 and July 30, 2025, Abivax received notices from entities affiliated with Heights Capital Management, which hold amortizing senior convertible notes issued in August 2023 (the “Height Convertible Notes”), for the conversion of 150 and 200 convertible notes, respectively (corresponding to the entirety of the outstanding principal amount of EUR 21.9 million) into 920,377 new ordinary shares of the Company at a conversion price of EUR 23.7674 per ordinary share in accordance with the terms and conditions of the convertible notes. Following these share issuances, Abivax no longer holds any debt with Heights Capital Management.

•On August 6, 2025, Kreos Capital VII(UK) Limited converted its portion of the Tranche A convertible OCABSA resulting in the issuance of 785,389 ordinary shares of the Company. In addition, on the same date Kreos Capital VII Aggregator SCSp exercised its share warrants (the tranche A-B BSA and tranche C BSA) resulting in the issuance of 319,251 ordinary shares of the Company.

•On August 28, 2025, Claret European Growth Capital Fund III SCSp, exercised its share warrants (the tranche A-B BSA and tranche C BSA) resulting in the issuance of 206,662 ordinary shares of the Company.

Based on (a) the Company’s existing cash and cash equivalents of EUR 60.9 million as of June 30, 2025, (b) the gross proceeds from the July 2025 underwritten public offering of EUR 637.5 million (c) the conversion of all 350 Heights convertible notes in July and August 2025 and (d) the conversion of the Kreos portion of the Tranche A convertible OCABSA (aggregate principle amount of EUR 16.7 million) , the Company expects, as of the date of issuance of the unaudited interim condensed consolidated financial statements included in the Company’s half-year report, to be able to fund its forecasted cash flow requirements into the fourth quarter of 2027.

*****

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at www.abivax.com. Follow us on LinkedIn and on X, formerly Twitter, @ABIVAX.

Contacts:

Abivax Investor Relations

Patrick Malloy

patrick.malloy@abivax.com

+1 847 987 4878

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, forecasts and estimates, including those relating to the Company’s business and financial objectives. Words such as “design,” “expect,” “forward,” “future,” “potential,” “plan,” “project,” “will” and variations of such words and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements concerning or implying the therapeutic potential of Abivax's drug candidates, Abivax’s cash runway, and other statements that are not historical fact. Although Abivax’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its universal registration document (Document d’Enregistrement Universel) and in its Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 24, 2025 under the caption “Risk Factors.” These risks, contingencies and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug candidate, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates. and the availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development including further assessment by the Company and regulatory agencies and IRBs/ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are made only as of the date of this press release. Readers are cautioned not to place undue

reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. Information about pharmaceutical products (including products currently in development) that is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgment. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.